☰

Ravi Salgia - Publications

Affiliations: 
Cancer Biology University of Chicago, Chicago, IL 
Area:
Oncology, Molecular Biology
Tree Info Grants Similar researchers PubMed Report error

500 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Ramisetty SK, Garg P, Mohanty A, Mirzapoiazova T, Yue E, Wang E, Horne D, Awasthi S, Kulkarni P, Salgia R, Singhal SS. Regression of ovarian cancer xenografts by depleting or inhibiting RLIP. Biochemical Pharmacology. 217: 115847. PMID 37804871 DOI: 10.1016/j.bcp.2023.115847  0.329
2023 Ebadi M, Ladbury C, Liu J, Rock A, Onyshchenko M, Villaflor V, Villalona-Calero M, Salgia R, Massarelli E, Lee P, Williams T, Amini A. Stereotactic Body Radiation Therapy for Oligoprogressive and Oligorecurrent Non-Small-Cell Lung Cancer. Clinical Lung Cancer. PMID 37714807 DOI: 10.1016/j.cllc.2023.08.015  0.335
2023 Liu J, Amini A, Govindarajan A, Abuali T, Mambetsariev I, Massarelli E, Villaflor V, Villalona-Calero M, West H, Williams T, Salgia R. Targeted Therapies in Early-Stage Resectable Non-Small-Cell Lung Cancer: New Kids on the Block. Jco Precision Oncology. 7: e2200445. PMID 37656950 DOI: 10.1200/PO.22.00445  0.331
2023 Shah A, Chaudhary S, Lakshmanan I, Aithal A, Kisling SG, Sorrell C, Marimuthu S, Gautam SK, Rauth S, Kshirsagar P, Cox JL, Natarajan G, Bhatia R, Mallya K, Rachagani S, ... ... Salgia R, et al. Chimeric antibody targeting unique epitope on onco-mucin16 reduces tumor burden in pancreatic and lung malignancies. Npj Precision Oncology. 7: 74. PMID 37567918 DOI: 10.1038/s41698-023-00423-7  0.341
2023 Guo L, Mohanty A, Singhal S, Srivastava S, Nam A, Warden C, Ramisetty S, Yuan YC, Cho H, Wu X, Li A, Vohra M, Saladi SV, Wheeler D, Arvanitis L, ... ... Salgia R, et al. Targeting ITGB4/SOX2-driven lung cancer stem cells using proteasome inhibitors. Iscience. 26: 107302. PMID 37554452 DOI: 10.1016/j.isci.2023.107302  0.357
2023 Sattler M, Salgia R. LSD1-targeted therapy-a multi-purpose key to unlock immunotherapy in small cell lung cancer. Translational Lung Cancer Research. 12: 1350-1354. PMID 37425423 DOI: 10.21037/tlcr-23-40  0.384
2023 Garcia D, Mambetsariev I, Fricke J, Schmolze D, Afkhami M, Mannan R, Kim P, Therese Dingal S, Nguyen B, Babikian R, Fong Y, Salgia R. Complete response to chemoimmunotherapy with bevacizumab in synchronous multiple primary cancers: pulmonary adenocarcinoma and sarcomatoid carcinoma. Cold Spring Harbor Molecular Case Studies. 9. PMID 37160318 DOI: 10.1101/mcs.a006262  0.368
2023 Kostecki KL, Iida M, Wiley AL, Kimani S, Mehall B, Tetreault K, Alexandridis R, Yu M, Hong S, Salgia R, Bruce JY, Birge RB, Harari PM, Wheeler DL. Dual Axl/MerTK inhibitor INCB081776 creates a proinflammatory tumor immune microenvironment and enhances anti-PDL1 efficacy in head and neck cancer. Head & Neck. PMID 36939040 DOI: 10.1002/hed.27340  0.324
2023 Sattler M, Mambetsariev I, Fricke J, Tan T, Liu S, Vaidehi N, Pisick E, Mirzapoiazova T, Rock AG, Merla A, Sharma S, Salgia R. A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision Medicine. Journal of Clinical Medicine. 12. PMID 36902723 DOI: 10.3390/jcm12051936  0.304
2023 Zarinshenas R, Amini A, Mambetsariev I, Abuali T, Fricke J, Ladbury C, Salgia R. Assessment of Barriers and Challenges to Screening, Diagnosis, and Biomarker Testing in Early-Stage Lung Cancer. Cancers. 15. PMID 36900386 DOI: 10.3390/cancers15051595  0.303
2023 Park K, Sabari JK, Haura EB, Shu CA, Spira A, Salgia R, Reckamp KL, Sanborn RE, Govindan R, Bauml JM, Curtin JC, Xie J, Roshak A, Lorenzini P, Millington D, et al. Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study. Lung Cancer (Amsterdam, Netherlands). 178: 166-171. PMID 36868177 DOI: 10.1016/j.lungcan.2023.02.008  0.314
2023 Sayer MR, Mambetsariev I, Lu KH, Wong CW, Duche A, Beuttler R, Fricke J, Pharoan R, Arvanitis L, Eftekhari Z, Amini A, Koczywas M, Massarelli E, Roosan MR, Salgia R. Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy. Frontiers in Oncology. 13: 1064169. PMID 36860308 DOI: 10.3389/fonc.2023.1064169  0.307
2023 Ladbury C, Abuali T, Liu J, Watkins W, Du D, Massarelli E, Villaflor V, Liu A, Salgia R, Williams T, Glaser S, Amini A. Prognostic Role of Biologically Active Volume of Disease in Patients With Metastatic Lung Adenocarcinoma. Clinical Lung Cancer. PMID 36759265 DOI: 10.1016/j.cllc.2023.01.001  0.349
2023 Ladbury C, Amini A, Govindarajan A, Mambetsariev I, Raz DJ, Massarelli E, Williams T, Rodin A, Salgia R. Integration of artificial intelligence in lung cancer: Rise of the machine. Cell Reports. Medicine. 100933. PMID 36738739 DOI: 10.1016/j.xcrm.2023.100933  0.316
2023 Khan P, Siddiqui JA, Kshirsagar PG, Venkata RC, Maurya SK, Mirzapoiazova T, Perumal N, Chaudhary S, Kanchan RK, Fatima M, Khan MA, Rehman AU, Lakshmanan I, Mahapatra S, Talmon GA, ... ... Salgia R, et al. MicroRNA-1 attenuates the growth and metastasis of small cell lung cancer through CXCR4/FOXM1/RRM2 axis. Molecular Cancer. 22: 1. PMID 36597126 DOI: 10.1186/s12943-022-01695-6  0.346
2022 Wing SE, Jankowska MM, Zou X, Sosa E, Yang JA, Benmarhnia T, Neuhausen SL, Nelson R, Salgia R, Gray SW, Erhunmwunsee L. Neighborhood disadvantage is associated with KRAS-mutated non-small cell lung cancer risk. Journal of Cancer Research and Clinical Oncology. PMID 36383274 DOI: 10.1007/s00432-022-04455-7  0.354
2022 Sattler M, Salgia R. Exploring the Next Frontier in Non-Small-Cell Lung Cancer With High MET and Mutated Epidermal Growth Factor Receptor. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2202086. PMID 36331252 DOI: 10.1200/JCO.22.02086  0.367
2022 Zhao D, Li H, Mambetsariev I, Mirzapoiazova T, Chen C, Fricke J, Kulkarni P, Villaflor V, Arvanitis L, Hamilton S, Afkhami M, Pillai R, Armstrong B, Erhunmwunsee L, Massarelli E, ... ... Salgia R, et al. Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. Cancers. 14. PMID 36230855 DOI: 10.3390/cancers14194933  0.352
2022 Srivastava S, Mohanty A, Nam A, Singhal S, Salgia R. Chemokines and NSCLC: Emerging role in prognosis, heterogeneity, and therapeutics. Seminars in Cancer Biology. PMID 35787939 DOI: 10.1016/j.semcancer.2022.06.010  0.395
2022 Zarinshenas R, Ladbury C, McGee H, Raz D, Erhunmwunsee L, Pathak R, Glaser S, Salgia R, Williams T, Amini A. Machine learning to refine prognostic and predictive nodal burden thresholds for post-operative radiotherapy in completely resected stage III-N2 non-small cell lung cancer. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 173: 10-18. PMID 35618098 DOI: 10.1016/j.radonc.2022.05.019  0.304
2022 Mirzapoiazova T, Xiao G, Mambetsariev B, Nasser MW, Miaou E, Singhal SS, Srivastava S, Mambetsariev I, Nelson MS, Nam A, Behal A, Arvanitis LD, Atri P, Muschen M, Tissot FLH, ... ... Salgia R, et al. Correction: Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer. Molecular Cancer Therapeutics. 21: 700. PMID 35373301 DOI: 10.1158/1535-7163.MCT-22-0104  0.339
2022 Mambetsariev I, Arvanitis L, Fricke J, Pharaon R, Baroz AR, Afkhami M, Koczywas M, Massarelli E, Salgia R. Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer. Journal of Clinical Medicine. 11. PMID 35268520 DOI: 10.3390/jcm11051429  0.358
2022 Salgia R. The next targets for small cell lung cancer. Clinical Advances in Hematology & Oncology : H&O. 20: 35-36. PMID 35060960  0.396
2022 Liu J, Bratton E, Yu X, Ladbury C, Wagner J, West H, Massarelli E, Salgia R, Pathak R, Villaflor V, Villalona-Calero M, Amini A. Patterns of Care in Maintenance Therapy in US Patients Undergoing Definitive Chemoradiation for Stage 3 Non-Small Cell Lung Cancer (NSCLC). American Journal of Clinical Oncology. PMID 34991107 DOI: 10.1097/COC.0000000000000886  0.373
2021 Nam A, Mohanty A, Bhattacharya S, Kotnala S, Achuthan S, Hari K, Srivastava S, Guo L, Nathan A, Chatterjee R, Jain M, Nasser MW, Batra SK, Rangarajan G, Massarelli E, ... ... Salgia R, et al. Dynamic Phenotypic Switching and Group Behavior Help Non-Small Cell Lung Cancer Cells Evade Chemotherapy. Biomolecules. 12. PMID 35053156 DOI: 10.3390/biom12010008  0.337
2021 Baroz AR, Mambetsariev I, Fricke J, Pharaon R, Tan T, Kidambi T, Sandhu KS, Koczywas M, Salgia R. Elevated Eosinophil Count Following Pembrolizumab Treatment for Non-Small Cell Lung Cancer. Cureus. 13: e16266. PMID 34377604 DOI: 10.7759/cureus.16266  0.309
2021 Pathak R, Amini A, Hill A, Massarelli E, Salgia R. Immunotherapy in Non-Small Cell Lung Cancer Patients with Brain Metastases: Clinical Challenges and Future Directions. Cancers. 13. PMID 34298620 DOI: 10.3390/cancers13143407  0.379
2021 Mirzapoiazova T, Xiao G, Mambetsariev B, Nasser MW, Miaou E, Singhal SS, Srivastava S, Mambetsariev I, Nelson MS, Nam A, Behal A, Atri P, Müschen M, Tissot FLH, Miser J, ... ... Salgia R, et al. Protein phosphatase 2A as a therapeutic target in small cell lung cancer. Molecular Cancer Therapeutics. PMID 34253596 DOI: 10.1158/1535-7163.MCT-21-0013  0.357
2021 Erhunmwunsee L, Wing SE, Shen J, Hu H, Sosa E, Lopez LN, Raquel C, Sur M, Ibarra-Noriega P, Currey M, Lee J, Kim JY, Raz DJ, Amini A, Sampath S, ... ... Salgia R, et al. The Association between Polluted Neighborhoods and TP53-Mutated Non-Small Cell Lung Cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 34088750 DOI: 10.1158/1055-9965.EPI-20-1555  0.322
2021 Roosan MR, Mambetsariev I, Pharaon R, Fricke J, Husain H, Reckamp KL, Koczywas M, Massarelli E, Bild AH, Salgia R. Utility of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients with Non-small Cell Lung Cancer. Chest. PMID 33878340 DOI: 10.1016/j.chest.2021.04.016  0.359
2021 Reckamp KL, Behrendt CE, Slavin TP, Gray SW, Castillo DK, Koczywas M, Cristea MC, Babski KM, Stearns D, Marcum CA, Rodriguez YP, Hass AJ, Vecchio MM, Mora P, Cervantes AE, ... ... Salgia R, et al. Germline mutations and age at onset of lung adenocarcinoma. Cancer. PMID 33858029 DOI: 10.1002/cncr.33573  0.306
2021 Liu J, Hui C, Ladbury C, Waddington T, Erhunmwunsee L, Raz D, Kim J, Salgia R, Chenery S, Pearlstein D, Schwer A, Amini A. Improved Survival Outcomes in Medically Fit Patients With Early-Stage Non-Small-Cell Lung Cancer Undergoing Stereotactic Body Radiotherapy. Clinical Lung Cancer. PMID 33712362 DOI: 10.1016/j.cllc.2021.01.003  0.349
2021 Singhal SS, Mohanty A, Kulkarni P, Horne D, Awasthi S, Salgia R. RLIP Depletion Induces Apoptosis Associated with Inhibition of JAK2/STAT3 Signaling in Melanoma Cells. Carcinogenesis. PMID 33623991 DOI: 10.1093/carcin/bgab016  0.319
2021 Aredo JV, Mambetsariev I, Hellyer JA, Amini A, Neal JW, Padda SK, McCoach CE, Riess JW, Cabebe EC, Naidoo J, Abuali T, Salgia R, Loo BW, Diehn M, Han SS, et al. Durvalumab for Stage III EGFR-Mutated Non-Small Cell Lung Cancer After Definitive Chemoradiotherapy. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 33588109 DOI: 10.1016/j.jtho.2021.01.1628  0.38
2021 Salgia R, Pharaon R, Mambetsariev I, Nam A, Sattler M. The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC). Cell Reports. Medicine. 2: 100186. PMID 33521700 DOI: 10.1016/j.xcrm.2020.100186  0.404
2021 Shah A, Singh H, Sachdev V, Lee J, Yotsukura S, Salgia R, Bharti A. DIFFERENTIAL SERUM LEVEL OF SPECIFIC HAPTOGLOBIN ISOFORMS IN SMALL CELL LUNG CANCER. Current Proteomics. 7: 49-65. PMID 20526421 DOI: 10.2174/157016410790979635  0.362
2020 Pathak R, Pharaon RR, Mohanty A, Villaflor VM, Salgia R, Massarelli E. Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure. Cancers. 12. PMID 33419311 DOI: 10.3390/cancers12123851  0.359
2020 Roth KG, Mambetsariev I, Salgia R. Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring exon 14 mutation: a research report. Cold Spring Harbor Molecular Case Studies. 6. PMID 33335011 DOI: 10.1101/mcs.a005785  0.419
2020 Khan P, Siddiqui JA, Maurya SK, Lakshmanan I, Jain M, Ganti AK, Salgia R, Batra SK, Nasser MW. Epigenetic Landscape of Small Cell Lung Cancer: Small Image of a Giant Recalcitrant Disease. Seminars in Cancer Biology. PMID 33220460 DOI: 10.1016/j.semcancer.2020.11.006  0.34
2020 Pharaon R, Mambetsariev I, Fricke J, Salgia R. Rapid progression of disease from immunotherapy following targeted therapy: insights into treatment management and sequence. Journal of Thoracic Disease. 12: 5096-5103. PMID 33145086 DOI: 10.21037/jtd.2019.08.14  0.33
2020 Amanam I, Mambetsariev I, Gupta R, Achuthan S, Wang Y, Pharaon R, Massarelli E, Koczywas M, Reckamp K, Salgia R. Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival. Journal of Thoracic Disease. 12: 5086-5095. PMID 33145085 DOI: 10.21037/Jtd.2020.04.18  0.504
2020 Cushman TR, Jones B, Akhavan D, Rusthoven CG, Verma V, Salgia R, Sedrak M, Massarelli E, Welsh JW, Amini A. The Effects of Time to Treatment Initiation for Patients With Non-small-cell Lung Cancer in the United States. Clinical Lung Cancer. PMID 33039348 DOI: 10.1016/J.Cllc.2020.09.004  0.483
2020 Mohanty A, Nam A, Pozhitkov A, Yang L, Srivastava S, Nathan A, Wu X, Mambetsariev I, Nelson M, Subbalakshmi AR, Guo L, Nasser MW, Batra SK, Orban J, Jolly MK, ... ... Salgia R, et al. A Non-genetic Mechanism Involving the Integrin β4/Paxillin Axis Contributes to Chemoresistance in Lung Cancer. Iscience. 23: 101496. PMID 32947124 DOI: 10.1016/J.Isci.2020.101496  0.392
2020 Subbiah S, Nam A, Garg N, Behal A, Kulkarni P, Salgia R. Small Cell Lung Cancer from Traditional to Innovative Therapeutics: Building a Comprehensive Network to Optimize Clinical and Translational Research. Journal of Clinical Medicine. 9. PMID 32751469 DOI: 10.3390/Jcm9082433  0.415
2020 Huang LS, Kotha SR, Avasarala S, VanScoyk M, Winn RA, Pennathur A, Yashaswini PS, Bandela M, Salgia R, Tyurina YY, Kagan VE, Zhu X, Reddy SP, Sudhadevi T, Punathil-Kannan PK, et al. Lysocardiolipin acyltransferase regulates NSCLC cell proliferation and migration by modulating mitochondrial dynamics. The Journal of Biological Chemistry. PMID 32732285 DOI: 10.1074/Jbc.Ra120.012680  0.5
2020 Amanam I, Mambetsariev I, Gupta R, Salgia R. Progressive Neurologic Changes in a Patient With Metastatic Non-Small-Cell Lung Cancer: Cancer Effects or a Secondary Diagnosis? Jco Oncology Practice. JOP1900701. PMID 32644904 DOI: 10.1200/JOP.19.00701  0.392
2020 Salgia R, Mambetsariev I, Pharaon R, Fricke J, Baroz AR, Hozo I, Chen C, Koczywas M, Massarelli E, Reckamp K, Djulbegovic B. Evaluation of Omics-Based Strategies for the Management of Advanced Lung Cancer. Jco Oncology Practice. OP2000117. PMID 32639928 DOI: 10.1200/Op.20.00117  0.452
2020 Malik R, Mambetsariev I, Fricke J, Chawla N, Nam A, Pharaon R, Salgia R. MET receptor in oncology: From biomarker to therapeutic target. Advances in Cancer Research. 147: 259-301. PMID 32593403 DOI: 10.1016/Bs.Acr.2020.04.006  0.455
2020 Salgia R, Mambetsariev I, Tan T, Schwer A, Pearlstein DP, Chehabi H, Baroz A, Fricke J, Pharaon R, Romo H, Waddington T, Babikian R, Buck L, Kulkarni P, Cianfrocca M, et al. Complex Oncological Decision-Making Utilizing Fast-and-Frugal Trees in a Community Setting-Role of Academic and Hybrid Modeling. Journal of Clinical Medicine. 9. PMID 32560187 DOI: 10.3390/Jcm9061884  0.307
2020 Zhao D, Mambetsariev I, Li H, Chen C, Fricke J, Fann P, Kulkarni P, Xing Y, Lee PP, Bild A, Massarelli E, Koczywas M, Reckamp K, Salgia R. Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors. Lung Cancer (Amsterdam, Netherlands). 146: 174-181. PMID 32554069 DOI: 10.1016/J.Lungcan.2020.05.025  0.501
2020 Rajurkar S, Mambetsariev I, Pharaon R, Leach B, Tan T, Kulkarni P, Salgia R. Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies. Journal of Clinical Medicine. 9. PMID 32549358 DOI: 10.3390/Jcm9061870  0.467
2020 Presant CA, Salgia R, Kulkarni P, Tiep BL, Sanani S, Leach B, Ashing K, Sandoval J, Sedrak MS, Landau S, Yeung S, Raz D, Subbiah S. Implementing Lung Cancer Screening and Prevention in Academic Centers, Affiliated Network Offices and Collaborating Care Sites. Journal of Clinical Medicine. 9. PMID 32545244 DOI: 10.3390/Jcm9061820  0.374
2020 Su R, Dong L, Li Y, Gao M, Han L, Wunderlich M, Deng X, Li H, Huang Y, Gao L, Li C, Zhao Z, Robinson S, Tan B, Qing Y, ... ... Salgia R, et al. Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. Cancer Cell. PMID 32531268 DOI: 10.1016/J.Ccell.2020.04.017  0.397
2020 Galvez C, Jacob S, Finkelman BS, Zhao J, Tegtmeyer K, Chae YK, Mohindra N, Salgia R, Jovanovic B, Behdad A, Villaflor V. The role of EGFR mutations in predicting recurrence in early and locally advanced lung adenocarcinoma following definitive therapy. Oncotarget. 11: 1953-1960. PMID 32523650 DOI: 10.18632/Oncotarget.27602  0.458
2020 McDaniel NK, Iida M, Nickel KP, Longhurst CA, Fischbach SR, Rodems TS, Kranjac CA, Bo AY, Luo Q, Gallagher MM, Welke NB, Mitchell KR, Schulz AE, Eckers JC, Hu R, ... Salgia R, et al. AXL mediates cetuximab and radiation resistance through tyrosine 821 and the c-ABL kinase pathway in head and neck cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32439698 DOI: 10.1158/1078-0432.Ccr-19-3142  0.333
2020 Singhal J, Chikara S, Horne D, Awasthi S, Salgia R, Singhal SS. Targeting RLIP with CRISPR/Cas9 controls tumor growth. Carcinogenesis. PMID 32426802 DOI: 10.1093/Carcin/Bgaa048  0.396
2020 Chen BT, Chen Z, Ye N, Mambetsariev I, Fricke J, Daniel E, Wang G, Wong CW, Rockne RC, Colen RR, Nasser MW, Batra SK, Holodny AI, Sampath S, Salgia R. Differentiating Peripherally-Located Small Cell Lung Cancer From Non-small Cell Lung Cancer Using a CT Radiomic Approach. Frontiers in Oncology. 10: 593. PMID 32391274 DOI: 10.3389/Fonc.2020.00593  0.467
2020 Jana S, Krishna M, Singhal J, Horne D, Awasthi S, Salgia R, Singhal SS. Therapeutic targeting of miRNA-216b in cancer. Cancer Letters. 484: 16-28. PMID 32387443 DOI: 10.1016/J.Canlet.2020.04.020  0.341
2020 Salgia R, Sattler M, Scheele J, Stroh C, Felip E. The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping. Cancer Treatment Reviews. 87: 102022. PMID 32334240 DOI: 10.1016/J.Ctrv.2020.102022  0.464
2020 Mirzapoiazova T, Pozhitkov A, Nam A, Mambetsariev I, Nelson MS, Tan YC, Zhang K, Raz D, Singhal S, Nasser MW, Kulkarni P, Batra SK, Sattler M, Salgia R. Effects of selected deubiquitinating enzyme inhibitors on the proliferation and motility of lung cancer and mesothelioma cell lines. International Journal of Oncology. PMID 32236606 DOI: 10.3892/Ijo.2020.5034  0.42
2020 Chen BT, Jin T, Ye N, Mambetsariev I, Daniel E, Wang T, Wong CW, Rockne RC, Colen R, Holodny AI, Sampath S, Salgia R. Radiomic prediction of mutation status based on MR imaging of lung cancer brain metastases. Magnetic Resonance Imaging. PMID 32179095 DOI: 10.1016/J.Mri.2020.03.002  0.413
2020 Strickler JH, LoRusso PM, Salgia R, Kang YK, Yen CJ, Lin CC, Ansell P, Motwani M, Wong S, Yue H, Wang L, Reilly EB, Afar DEH, Naumovski L, Ramanathan RK. Phase 1 Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients With Advanced Solid Tumors. Molecular Cancer Therapeutics. PMID 32127466 DOI: 10.1158/1535-7163.Mct-19-0529  0.303
2020 Mambetsariev I, Wang Y, Chen C, Nadaf S, Pharaon R, Fricke J, Amanam I, Amini A, Bild A, Chu P, Erhunmwunsee L, Kim J, Munu J, Pillai R, Raz D, ... ... Salgia R, et al. Precision medicine and actionable alterations in lung cancer: A single institution experience. Plos One. 15: e0228188. PMID 32045431 DOI: 10.1371/Journal.Pone.0228188  0.338
2020 Jana S, Krishna BM, Singhal J, Horne D, Awasthi S, Salgia R, Singhal SS. SOX9: The Master Regulator of Cell Fate in Breast Cancer. Biochemical Pharmacology. 113789. PMID 31911091 DOI: 10.1016/J.Bcp.2019.113789  0.382
2020 Singhal SS, Salgia R, Verma N, Horne D, Awasthi S. RLIP controls receptor-ligand signaling by regulating clathrin-dependent endocytosis. Biochimica Et Biophysica Acta. Reviews On Cancer. 1873: 188337. PMID 31904398 DOI: 10.1016/J.Bbcan.2020.188337  0.31
2020 Chung V, Frankel PH, Shibata S, Mambetsariev I, Yin H, Mirzapoiazova T, Mambetsariev B, Kulkarni P, Lim D, Li D, Chao J, Fakih M, Bild A, Pillai RK, Adalsteinsson O, ... ... Salgia R, et al. Gene expression profiling of unresectable pancreatic cancer patients treated with gemcitabine, nab-paclitaxel, metformin, and dietary supplements (DS). Journal of Clinical Oncology. 38: 736-736. DOI: 10.1200/Jco.2020.38.4_Suppl.736  0.346
2020 Owonikoko TK, Borghaei H, Champiat S, Paz-Ares LG, Govindan R, Boyer MJ, Johnson ML, Udagawa H, Hummel H, Salgia R, Blackhall FH, Boosman RJ, Lai WV, Dowlati A, Vokes EE, et al. Phase I study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in patients with small cell lung cancer (SCLC). Journal of Clinical Oncology. 38: TPS9080-TPS9080. DOI: 10.1200/Jco.2020.38.15_Suppl.Tps9080  0.409
2020 Baroz AR, Mambetsariev I, Fricke J, Pharaon R, Zhao D, Koczywas M, Massarelli E, Salgia R. Evaluation of immune-related adverse events in patients treated with sequential immunotherapy and tyrosine kinase inhibitor treatment in non-small cell lung cancer. Journal of Clinical Oncology. 38: e21562-e21562. DOI: 10.1200/Jco.2020.38.15_Suppl.E21562  0.396
2020 Fricke J, Mambetsariev I, Pharaon R, Baroz AR, Zhao D, Massarelli E, Koczywas M, Salgia R. Alterations in STK11 to limit response to immune checkpoint inhibitors in lung cancer. Journal of Clinical Oncology. 38: e21503-e21503. DOI: 10.1200/Jco.2020.38.15_Suppl.E21503  0.427
2020 Salgia R, Boehmer L, Celestin C, Yu J, Spigel DR. Improving care for patients with stage III/IV NSCLC: Learnings for multidisciplinary teams from the ACCC national quality survey. Journal of Clinical Oncology. 38: e19195-e19195. DOI: 10.1200/Jco.2020.38.15_Suppl.E19195  0.373
2020 Erhunmwunsee L, Hu H, Raquel C, Lopez LN, Shen J, Wong L, Kim JY, Raz DJ, Reckamp KL, Salgia R, Gray SW. Abstract PR08: Neighborhood-level social determinants impact non-small cell lung cancer aggressive somatic phenotypes Cancer Epidemiology, Biomarkers & Prevention. DOI: 10.1158/1538-7755.Disp19-Pr08  0.431
2020 Zhao D, Mambetsariev I, Li H, Chen C, Fricke J, Fann P, Kulkarni P, Xing Y, Lee P, Bild A, Massarelli E, Koczywas M, Reckamp K, Salgia R. Abstract 3300: Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors Immunology. 80: 3300-3300. DOI: 10.1158/1538-7445.Am2020-3300  0.483
2020 Mohanty A, Nam A, Pozhitkov A, Yang L, Nelson M, Wu X, Kulkarni P, Massarelli E, Salgia R. Abstract 2607: Integrin Beta4/Paxillin mediated chemoresistance in lung adenocarcinoma Cancer Research. 80: 2607-2607. DOI: 10.1158/1538-7445.Am2020-2607  0.496
2020 Amini A, Chau B, Mambetsariev I, Huntzinger C, Shirvani S, Reckamp K, Massarelli E, Wong J, Salgia R. Expanding the Definition of Oligometastatic in Lung Adenocarcinoma International Journal of Radiation Oncology Biology Physics. 108. DOI: 10.1016/J.Ijrobp.2020.02.588  0.398
2020 Amini A, Chau B, Mambetsariev I, Huntzinger C, Shirvani S, Koczywas M, Reckamp K, Massarelli E, Wong J, Salgia R. Prognostic Impact of Malignant Pleural Effusion in Patients with Oligometastatic Lung Adenocarcinoma International Journal of Radiation Oncology Biology Physics. 108. DOI: 10.1016/J.Ijrobp.2020.02.586  0.405
2019 Griffiths JI, Cohen AL, Jones V, Salgia R, Chang JT, Bild AH. Opportunities for improving cancer treatment using systems biology. Current Opinion in Systems Biology. 17: 41-50. PMID 32518857 DOI: 10.1016/J.Coisb.2019.10.018  0.385
2019 Zhang K, Yang L, Wang J, Sun T, Guo Y, Nelson R, Tong TR, Pangeni R, Salgia R, Raz DJ. Ubiquitin-specific protease 22 is critical to in vivo angiogenesis, growth and metastasis of non-small cell lung cancer. Cell Communication and Signaling : Ccs. 17: 167. PMID 31842906 DOI: 10.1186/S12964-019-0480-X  0.511
2019 Clark JW, Camidge DR, Kwak EL, Maki RG, Shapiro GI, Chen I, Tan W, Randolph S, Christensen JG, Ozeck M, Tang Y, Wilner KD, Salgia R. Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer. Future Oncology (London, England). PMID 31778074 DOI: 10.2217/Fon-2019-0653  0.303
2019 Nardi IK, Stark JM, Larsen A, Salgia R, Raz DJ. USP22 interacts with PALB2 and promotes chemotherapy resistance via homologous recombination of DNA double strand breaks. Molecular Cancer Research : McR. PMID 31685642 DOI: 10.1158/1541-7786.Mcr-19-0053  0.358
2019 Kalvala A, Wallet P, Yang L, Wang C, Li H, Nam A, Nathan A, Mambetsariev I, Poroyko V, Gao H, Chu P, Sattler M, Bild A, Manuel ER, Lee PP, ... ... Salgia R, et al. Phenotypic Switching of Naïve T Cells to Immune-Suppressive Treg-Like Cells by Mutant KRAS. Journal of Clinical Medicine. 8. PMID 31635338 DOI: 10.3390/Jcm8101726  0.405
2019 Mirzapoiazova T, Li H, Nathan A, Srivstava S, Nasser MW, Lennon F, Armstrong B, Mambetsariev I, Chu PG, Achuthan S, Batra SK, Kulkarni P, Salgia R. Monitoring and Determining Mitochondrial Network Parameters in Live Lung Cancer Cells. Journal of Clinical Medicine. 8. PMID 31635288 DOI: 10.3390/Jcm8101723  0.341
2019 Tan YC, Srivastava S, Won BM, Kanteti R, Arif Q, Husain AN, Li H, Vigneswaran WT, Pang KM, Kulkarni P, Sattler M, Vaidehi N, Mambetsariev I, Kindler HL, Wheeler DL, ... Salgia R, et al. EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma. Oncogenesis. 8: 49. PMID 31484920 DOI: 10.1038/s41389-019-0159-6  0.383
2019 Gill RR, Tsao AS, Kindler HL, Richards WG, Armato SG, Francis RJ, Gomez DR, Dahlberg S, Rimner A, Simone CB, de Perrot M, Blumenthal G, Adjei AA, Bueno R, Harpole DH, ... ... Salgia R, et al. Radiologic Considerations And Standardization Of Malignant Pleural Mesothelioma (MPM) Imaging Within Clinical Trials: Consensus Statement From The NCI Thoracic Malignancy Steering Committee - International Association For The Study Of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 31470129 DOI: 10.1016/J.Jtho.2019.08.012  0.367
2019 Roth KG, Mambetsariev I, Kulkarni P, Salgia R. The Mitochondrion as an Emerging Therapeutic Target in Cancer. Trends in Molecular Medicine. PMID 31327706 DOI: 10.1016/J.Molmed.2019.06.009  0.421
2019 Krishna BM, Jana S, Singhal J, Horne D, Awasthi S, Salgia R, Singhal SS. Notch signaling in breast cancer: From pathway analysis to therapy. Cancer Letters. 461: 123-131. PMID 31326555 DOI: 10.1016/J.Canlet.2019.07.012  0.409
2019 Mambetsariev I, Mirzapoiazova T, Lennon F, Jolly MK, Li H, Nasser MW, Vora L, Kulkarni P, Batra SK, Salgia R. Small Cell Lung Cancer Therapeutic Responses Through Fractal Measurements: From Radiology to Mitochondrial Biology. Journal of Clinical Medicine. 8. PMID 31315252 DOI: 10.3390/Jcm8071038  0.439
2019 Tsao MS, Carbone M, Galateau-Salle F, Moreira AL, Nicholson AG, Roden AC, Adjei AA, Aubry MC, Fennell DA, Gomez D, Harpole D, Hesdorffer M, Hirsch FR, Liu G, Malik S, ... ... Salgia R, et al. Pathologic considerations and standardization in mesothelioma clinical trials. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 31260832 DOI: 10.1016/J.Jtho.2019.06.020  0.367
2019 Hill A, Gupta R, Zhao D, Vankina R, Amanam I, Salgia R. Targeted Therapies in Non-small-Cell Lung Cancer. Cancer Treatment and Research. 178: 3-43. PMID 31209840 DOI: 10.1007/978-3-030-16391-4_1  0.498
2019 Shinde A, Horne ZD, Li R, Glaser S, Massarelli E, Koczywas M, Erhunmwunsee L, Reckamp KL, Weksler B, Salgia R, Beriwal S, Amini A. Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio. Lung Cancer (Amsterdam, Netherlands). 133: 136-143. PMID 31200820 DOI: 10.1016/J.Lungcan.2019.05.020  0.42
2019 Singhal SS, Horne D, Singhal J, Vonderfecht S, Salgia R, Awasthi S. Synergistic efficacy of RLIP inhibition and 2'-hydroxyflavanone against DMBA-induced mammary carcinogenesis in SENCAR mice. Molecular Carcinogenesis. PMID 31006917 DOI: 10.1002/Mc.23026  0.301
2019 Wang C, Kulkarni P, Salgia R. Combined Checkpoint Inhibition and Chemotherapy: New Era of 1-Line Treatment for Non-Small-Cell Lung Cancer. Molecular Therapy Oncolytics. 13: 1-6. PMID 30976658 DOI: 10.1016/J.Omto.2019.02.001  0.465
2019 Amini A, Verma V, Glaser SM, Shinde A, Sampath S, Stokes WA, Rusthoven CG, Massarelli E, Salgia R, Gaspar LE, Liu AK. Early mortality of stage IV non-small cell lung cancer in the United States. Acta Oncologica (Stockholm, Sweden). 1-7. PMID 30958075 DOI: 10.1080/0284186X.2019.1599138  0.451
2019 Singhal SS, Salgia R, Singhal S, Horne D, Awasthi S. RLIP: An existential requirement for breast carcinogenesis. Biochimica Et Biophysica Acta. Reviews On Cancer. 1871: 281-288. PMID 30771458 DOI: 10.1016/J.Bbcan.2019.02.001  0.377
2019 Gupta R, Amanam I, Rahmanuddin S, Mambetsariev I, Wang Y, Huang C, Reckamp K, Vora L, Salgia R. Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma. American Journal of Clinical Oncology. PMID 30741758 DOI: 10.1097/Coc.0000000000000508  0.487
2019 Singhal J, Chikara S, Horne D, Salgia R, Awasthi S, Singhal SS. RLIP inhibition suppresses breast-to-lung metastasis. Cancer Letters. 447: 24-32. PMID 30684594 DOI: 10.1016/J.Canlet.2019.01.023  0.412
2019 Hewelt B, Li H, Jolly MK, Kulkarni P, Mambetsariev I, Salgia R. The DNA Walk and its Demonstration of Deterministic Chaos- Relevance to Genomic Alterations in Lung Cancer. Bioinformatics (Oxford, England). PMID 30615123 DOI: 10.1093/Bioinformatics/Bty1021  0.323
2019 Sattler M, Salgia R. The MET axis as a therapeutic target. Update On Cancer Therapeutics. 3: 109-118. PMID 20368753 DOI: 10.1016/J.Uct.2009.01.001  0.37
2019 Scott A, Salgia R. Biomarkers in lung cancer: from early detection to novel therapeutics and decision making. Biomarkers in Medicine. 2: 577-586. PMID 19802373 DOI: 10.2217/17520363.2.6.577  0.458
2019 Smit MD, Borghaei H, Owonikoko TK, Hummel H, Johnson ML, Champiat S, Salgia R, Udagawa H, Boyer MJ, Govindan R. Phase 1 study of AMG 757, a half-life extended bispecific T cell engager (BiTE) antibody construct targeting DLL3, in patients with small cell lung cancer (SCLC). Journal of Clinical Oncology. 37: TPS8577-TPS8577. DOI: 10.1200/Jco.2019.37.15_Suppl.Tps8577  0.368
2019 Mambetsariev I, Djulbegovic B, Pharaon R, Hewelt B, Massarelli E, Koczywas M, Reckamp KL, Salgia R. Precision medicine for lung cancer decision-making: Evaluation of an -omics based FFT approach to personalized medicine. Journal of Clinical Oncology. 37: e20713-e20713. DOI: 10.1200/Jco.2019.37.15_Suppl.E20713  0.367
2019 Mambetsariev I, Nadaf S, Wang Y, Chen C, Hewelt B, Pharaon R, Massarelli E, Koczywas M, Reckamp KL, Salgia R. Precision medicine and actionable alterations in lung cancer. Journal of Clinical Oncology. 37: e20707-e20707. DOI: 10.1200/Jco.2019.37.15_Suppl.E20707  0.338
2019 Amanam IU, Chlebowski RT, Nelson RA, Salgia R. Lung cancer in African-Americans and analysis of estrogen plus progestin use. Journal of Clinical Oncology. 37: e18258-e18258. DOI: 10.1200/Jco.2019.37.15_Suppl.E18258  0.385
2019 Zhao D, Mambetsariev I, Chen C, Li H, Fricke J, Hewelt B, Fann P, Kulkarni P, Xing Y, Koczywas M, Massarelli E, Reckamp KL, Salgia R. Molecular and clinical features of hospital admissions and immunotherapy related adverse events of immune checkpoint inhibitors in thoracic malignancies. Journal of Clinical Oncology. 37: e18192-e18192. DOI: 10.1200/Jco.2019.37.15_Suppl.E18192  0.386
2019 Brahmer JR, Johnson ML, Dols MC, Viteri Ramirez S, Coves J, Sukari A, Awad MM, Salgia R, Papadimitrakopoulou V, Rajan A, Allred AJ, Wade M, Mason G, Zudaire E, Knoblauch RE, et al. Preliminary immunogenicity, safety, and efficacy of JNJ-64041757 (JNJ-757) in non-small cell lung cancer (NSCLC): Results from two phase 1 studies. Journal of Clinical Oncology. 37: 9093-9093. DOI: 10.1200/Jco.2019.37.15_Suppl.9093  0.362
2019 Reckamp KL, Slavin TP, Gray SW, Behrendt CE, Castillo D, Koczywas M, Cristea MC, Babski K, Stearns D, Marcum CA, Rodriguez Y, Hass A, Vecchio M, Mora Alferez AP, Cervantes A, ... ... Salgia R, et al. Germline mutations and onset of lung adenocarcinoma in smokers and nonsmokers. Journal of Clinical Oncology. 37: 1518-1518. DOI: 10.1200/Jco.2019.37.15_Suppl.1518  0.383
2019 Chung V, Frankel P, Shibata S, Mambetsariev I, Yin H, Mirzapoiazova T, Mambetsariev B, Kulkarni P, Lim D, Li D, Chao J, Fakih M, Bild A, Pillai R, Adalsteinsson O, ... ... Salgia R, et al. Abstract B13: Pilot trial of gemcitabine, nab-paclitaxel, metformin, and a standardized dietary supplement in patients with unresectable pancreatic cancer Clinical Trials. 79. DOI: 10.1158/1538-7445.Panca19-B13  0.354
2019 Singhal SS, Chikara S, Singhal J, Horne D, Salgia R, Awasthi S. Abstract 4801: 2’-Hydroxyflavanone, a diet-derived citrus bioflavonoid, inhibitsin vitroandin vivogrowth of breast cancer cells by targeting RLIP Cancer Research. 79: 4801-4801. DOI: 10.1158/1538-7445.Am2019-4801  0.381
2019 Gautam SK, Kanchan R, Atri P, Siddiqui J, Rauth S, Mahapatra S, Jain M, Moorthy PP, Salgia R, Band V, Batra SK, Nasser MW. Abstract 2017: Blocking ErbB-c-Met-FAK signaling axis suppresses brain metastasis of breast cancer Cancer Research. 79: 2017-2017. DOI: 10.1158/1538-7445.Am2019-2017  0.411
2019 McDaniel NK, Iida M, Nickel KP, Rodems TS, Swick AD, Prabakaran PJ, Eckers-Kubatzke JC, Welke NB, Kranjac C, Schulz AE, Kimple RJ, Salgia R, Wheeler DL. Abstract A128: AXL mediates cetuximab resistance through tyrosine 821 and activation of c-Abl kinase in head and neck cancer Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-A128  0.4
2019 Amini A, Shinde A, Li R, Ituarte P, Vazquez J, Glaser S, Massarelli E, Erhunmwunsee L, Salgia R, Ashing K. Disparate Outcomes in Non-Small Cell Lung Cancer By Race and Immigrant Status International Journal of Radiation Oncology*Biology*Physics. 105: E444-E445. DOI: 10.1016/J.Ijrobp.2019.06.1481  0.45
2019 Amini A, Li R, Liu A, Ray P, Maniyedath A, Huntzinger C, Shirvani S, Wong J, Rahmanuddin S, Salgia R. Number of Metastatic Organ Sites and Survival by Molecular Profile in Lung Adenocarcinoma International Journal of Radiation Oncology*Biology*Physics. 104: 1191-1192. DOI: 10.1016/J.Ijrobp.2019.05.049  0.367
2019 Shinde A, Li R, Glaser S, Massarelli E, Koczywas M, Reckamp K, Salgia R, Amini A. Role of Adjuvant Therapy in Clinically N2 Non-Small Cell Lung Cancer Patients Undergoing Neoadjuvant Chemotherapy and Surgery International Journal of Radiation Oncology*Biology*Physics. 104: 242-243. DOI: 10.1016/J.Ijrobp.2019.01.041  0.444
2018 Mason C, Ellis PG, Lokay K, Barry A, Dickson N, Page R, Polite B, Salgia R, Savin M, Shamah C, Socinski MA. Patterns of Biomarker Testing Rates and Appropriate Use of Targeted Therapy in the First-Line, Metastatic Non-Small Cell Lung Cancer Treatment Setting. Journal of Clinical Pathways : the Foundation of Value-Based Care. 4: 49-54. PMID 31453358 DOI: 10.25270/jcp.2018.02.00001  0.302
2018 Wang J, Mirzapoiazova T, Carol Tan YH, Pang KM, Pozhitkov A, Wang Y, Wang Y, Mambetsariev B, Wang E, Nasser MW, Batra SK, Raz D, Reckamp K, Kulkarni P, Zheng Y, ... Salgia R, et al. Inhibiting crosstalk between MET signaling and mitochondrial dynamics and morphology: a novel therapeutic approach for lung cancer and mesothelioma. Cancer Biology & Therapy. 1-10. PMID 30311833 DOI: 10.1080/15384047.2018.1472193  0.488
2018 Gong J, Hendifar A, Tuli R, Chuang J, Cho M, Chung V, Li D, Salgia R. Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade. Clinical and Translational Medicine. 7: 32. PMID 30294755 DOI: 10.1186/S40169-018-0210-9  0.38
2018 Shinde A, Li R, Kim J, Salgia R, Hurria A, Amini A. Stereotactic body radiation therapy (SBRT) for early-stage lung cancer in the elderly. Seminars in Oncology. PMID 30286944 DOI: 10.1053/J.Seminoncol.2018.06.002  0.41
2018 Tsao AS, Lindwasser OW, Adjei AA, Adusumilli PS, Beyers M, Blumenthal GM, Bueno R, Burt BM, Carbone M, Dahlberg SE, de Perrot M, Fennell DA, Friedberg J, Gill RR, Gomez DR, ... ... Salgia R, et al. Current and Future Management of Malignant Mesothelioma : A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer and Mesothelioma Applied Research Foundation. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 30266660 DOI: 10.1016/J.Jtho.2018.08.2036  0.409
2018 Nagaprashantha LD, Singhal J, Chikara S, Gugiu G, Horne D, Awasthi S, Salgia R, Singhal SS. 2'-Hydroxyflavanone induced changes in the proteomic profile of breast cancer cells. Journal of Proteomics. PMID 30248461 DOI: 10.1016/J.Jprot.2018.09.005  0.367
2018 Singhal J, Singhal P, Horne D, Salgia R, Awasthi S, Singhal SS. Metastasis of Breast Tumor Cells to Brain is suppressed by Targeting RLIP alone and in combination with 2'-Hydroxyflavanone. Cancer Letters. PMID 30223070 DOI: 10.1016/J.Canlet.2018.09.015  0.341
2018 Singhal J, Chikara S, Horne D, Salgia R, Awasthi S, Singhal SS. 2'-Hydroxyflavanone inhibits in vitro and in vivo growth of breast cancer cells by targeting RLIP76. Molecular Carcinogenesis. PMID 30136444 DOI: 10.1002/Mc.22894  0.401
2018 Hill A, Gong J, Wilczynski S, Mirza R, Erhunmwunsee L, Salgia R. Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non-Small-Cell Lung Cancer. Journal of Oncology Practice. JOP1800127. PMID 30044685 DOI: 10.1200/Jop.18.00127  0.439
2018 Mambetsariev I, Pharaon R, Nam A, Knopf K, Djulbegovic B, Villaflor VM, Vokes EE, Salgia R. Heuristic value-based framework for lung cancer decision-making. Oncotarget. 9: 29877-29891. PMID 30042820 DOI: 10.18632/Oncotarget.25643  0.361
2018 Sehdev A, Karrison T, Zha Y, Janisch L, Turcich M, Cohen EEW, Maitland M, Polite BN, Gajewski TF, Salgia R, Pinto N, Bissonnette MB, Fleming GF, Ratain MJ, Sharma MR. A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. PMID 29948021 DOI: 10.1007/s00280-018-3619-3  0.338
2018 Salgia R, Jolly MK, Dorff T, Lau C, Weninger K, Orban J, Kulkarni P. Prostate-Associated Gene 4 (PAGE4): Leveraging the Conformational Dynamics of a Dancing Protein Cloud as a Therapeutic Target. Journal of Clinical Medicine. 7. PMID 29914187 DOI: 10.3390/Jcm7060156  0.326
2018 Salgia R, Mambetsariev I, Hewelt B, Achuthan S, Li H, Poroyko V, Wang Y, Sattler M. Modeling small cell lung cancer (SCLC) biology through deterministic and stochastic mathematical models. Oncotarget. 9: 26226-26242. PMID 29899855 DOI: 10.18632/Oncotarget.25360  0.447
2018 Gong J, Salgia R. Managing Patients With Relapsed Small-Cell Lung Cancer. Journal of Oncology Practice. 14: 359-366. PMID 29894664 DOI: 10.1200/Jop.18.00204  0.419
2018 Poroyko V, Mirzapoiazova T, Nam A, Mambetsariev I, Mambetsariev B, Wu X, Husain A, Vokes EE, Wheeler DL, Salgia R. Exosomal miRNAs species in the blood of small cell and non-small cell lung cancer patients. Oncotarget. 9: 19793-19806. PMID 29731983 DOI: 10.18632/Oncotarget.24857  0.434
2018 Raghav K, Bailey AM, Loree JM, Kopetz S, Holla V, Yap TA, Wang F, Chen K, Salgia R, Hong D. Untying the gordion knot of targeting MET in cancer. Cancer Treatment Reviews. 66: 95-103. PMID 29730462 DOI: 10.1016/J.Ctrv.2018.04.008  0.408
2018 Nagaprashantha LD, Singhal J, Li H, Warden C, Liu X, Horne D, Awasthi S, Salgia R, Singhal SS. 2'-Hydroxyflavanone effectively targets RLIP76-mediated drug transport and regulates critical signaling networks in breast cancer. Oncotarget. 9: 18053-18068. PMID 29719590 DOI: 10.18632/Oncotarget.24720  0.373
2018 Xiao G, Chan LN, Klemm L, Braas D, Chen Z, Geng H, Zhang QC, Aghajanirefah A, Cosgun KN, Sadras T, Lee J, Mirzapoiazova T, Salgia R, Ernst T, Hochhaus A, et al. B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies. Cell. PMID 29551267 DOI: 10.1016/J.Cell.2018.02.048  0.306
2018 Urbanic JJ, Wang X, Bogart JA, Stinchcombe TE, Hodgson L, Schild SE, Bazhenova L, Hahn O, Salgia R, Vokes EE. Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance). International Journal of Radiation Oncology, Biology, Physics. PMID 29487024 DOI: 10.1016/J.Ijrobp.2018.01.046  0.44
2018 Salgia R, Kulkarni P. The Genetic/Non-genetic Duality of Drug 'Resistance' in Cancer. Trends in Cancer. 4: 110-118. PMID 29458961 DOI: 10.1016/J.Trecan.2018.01.001  0.32
2018 Amanam I, Gupta R, Mambetsariev I, Salgia R. The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer. Future Oncology (London, England). PMID 29451020 DOI: 10.2217/Fon-2017-0545  0.532
2018 Salgia R, Kulkarni P, Gill PS. EphB4: A promising target for upper Aerodigestive malignancies. Biochimica Et Biophysica Acta. PMID 29369779 DOI: 10.1016/J.Bbcan.2018.01.003  0.459
2018 Kanteti R, Mirzapoiazova T, Riehm JJ, Dhanasingh I, Mambetsariev B, Wang J, Kulkarni P, Kaushik G, Seshacharyulu P, Ponnusamy MP, Kindler HL, Nasser MW, Batra SK, Salgia R. Focal Adhesion Kinase a Potential Therapeutic Target for Pancreatic Cancer and Malignant Pleural Mesothelioma. Cancer Biology & Therapy. 0. PMID 29303405 DOI: 10.1080/15384047.2017.1416937  0.475
2018 Gupta R, Amanam IU, Salgia R, Mambetsariev I, Wang Y. Anaplastic lymphoma kinase (ALK) positive tumors: Clinical, radiographic and genomic characteristics, and unusual sites of metastases. Journal of Clinical Oncology. 36: e21130-e21130. DOI: 10.1200/Jco.2018.36.15_Suppl.E21130  0.463
2018 Subbiah V, Cascone T, Hess KR, Subbiah IM, Nelson S, Morikawa N, Nilsson MB, Bhatt T, Ali S, William WN, Raymond VM, Lanman RB, Carbone DP, Salgia R, Owonikoko TK, et al. Multi-kinase RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with RET rearranged non-small cell lung cancer. Journal of Clinical Oncology. 36: 9035-9035. DOI: 10.1200/Jco.2018.36.15_Suppl.9035  0.476
2018 McHenry AJ, Sondarva G, Ananthanarayanan V, Hess A, Simms PE, Alsayed A, Kataoka H, Marusarz J, Kumar S, Salgia R, Dudek A, Borowicz S, Rana A. Abstract 5514: Loss of hepatocyte growth factor activator inhibitor type-1 (HAI-1) in human lung adenocarcinomas promotes RON receptor phosphorylation and increased sensitivity to crizotinib Cancer Research. 78: 5514-5514. DOI: 10.1158/1538-7445.Am2018-5514  0.461
2018 Amini A, Glaser S, Akhavan D, Li R, Nelson R, Stokes W, Koczywas M, Reckamp K, Salgia R, Gaspar L, Kavanagh B, Rusthoven C, Liu A. Factors Predicting for Early Mortality in Non-Small Cell Lung Cancer International Journal of Radiation Oncology*Biology*Physics. 102: e670-e671. DOI: 10.1016/J.Ijrobp.2018.07.1813  0.441
2017 Lukas RV, Gondi V, Kamson DO, Kumthekar P, Salgia R. State-of-the-art considerations in small cell lung cancer brain metastases. Oncotarget. 8: 71223-71233. PMID 29050358 DOI: 10.18632/Oncotarget.19333  0.455
2017 Bhanot H, Weisberg EL, Reddy MM, Nonami A, Neuberg D, Stone RM, Podar K, Salgia R, Griffin JD, Sattler M. Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming. Oncotarget. 8: 67639-67650. PMID 28978059 DOI: 10.18632/Oncotarget.18797  0.345
2017 Yuan Y, Yost SE, Yim J, Yuan YC, Solomon NM, Mambetsariev I, Pal S, Frankel P, Salgia R, Neuhausen SL, Mortimer J. Correction: Genomic mutation-driven metastatic breast cancer therapy: a single center experience. Oncotarget. 8: 62817. PMID 28977992 DOI: 10.18632/Oncotarget.20632  0.31
2017 Reynolds KL, Bedard PL, Lee SH, Lin CC, Tabernero J, Alsina M, Cohen E, Baselga J, Blumenschein G, Graham DM, Garrido-Laguna I, Juric D, Sharma S, Salgia R, Seroutou A, et al. A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer. Bmc Cancer. 17: 646. PMID 28899363 DOI: 10.1186/S12885-017-3641-6  0.355
2017 Tan YC, Mirzapoiazova T, Won BM, Zhu L, Srivastava MK, Vokes EE, Husain AN, Batra SK, Sharma S, Salgia R. Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL. Scientific Reports. 7: 9192. PMID 28835699 DOI: 10.1038/S41598-017-09078-4  0.476
2017 Lukas RV, Gondi V, Kamson DO, Kumthekar P, Salgia R. State-of-the-art considerations in small cell lung cancer brain metastases. Oncotarget. PMID 28746911 DOI: 10.18632/oncotarget.19333  0.347
2017 Reb A, Ruel N, Fakih M, Lai L, Salgia R, Ferrell B, Sampath S, Kim JY, Raz DJ, Sun V. Empowering survivors after colorectal and lung cancer treatment: Pilot study of a Self-Management Survivorship Care Planning intervention. European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society. 29: 125-134. PMID 28720259 DOI: 10.1016/J.Ejon.2017.06.003  0.354
2017 Wood K, Byron E, Janisch L, Salgia R, Sharma MR. Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms. American Journal of Clinical Oncology. PMID 28654574 DOI: 10.1097/Coc.0000000000000400  0.302
2017 Little EC, Kubic JD, Salgia R, Grippo PJ, Lang D. Canonical and alternative transcript expression of PAX6 and CXCR4 in pancreatic cancer. Oncology Letters. 13: 4027-4034. PMID 28588695 DOI: 10.3892/Ol.2017.5956  0.377
2017 Zhang K, Wang J, Tong TR, Wu X, Nelson R, Yuan YC, Reno T, Liu Z, Yun X, Kim JY, Salgia R, Raz DJ. Loss of H2B monoubiquitination is associated with poor-differentiation and enhanced malignancy of lung adenocarcinoma. International Journal of Cancer. PMID 28481029 DOI: 10.1002/Ijc.30769  0.507
2017 Mok TSK, Crino L, Felip E, Salgia R, De Pas T, Tan DSW, Chow LQM. The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy. Cancer Treatment Reviews. 55: 181-189. PMID 28427013 DOI: 10.1016/J.Ctrv.2017.03.006  0.444
2017 Salgia R. MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale. Molecular Cancer Therapeutics. 16: 555-565. PMID 28373408 DOI: 10.1158/1535-7163.Mct-16-0472  0.488
2017 Salgia R, Weaver RW, McCleod M, Stille JR, Yan SB, Roberson S, Polzer J, Flynt A, Raddad E, Peek VL, Wijayawardana SR, Um SL, Gross S, Connelly MC, Morano C, et al. Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study. Investigational New Drugs. PMID 28299514 DOI: 10.1007/S10637-017-0446-Z  0.374
2017 Salgia R, Stille JR, Weaver RW, McCleod M, Hamid O, Polzer J, Roberson S, Flynt A, Spigel DR. A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 105: 7-13. PMID 28236984 DOI: 10.1016/J.Lungcan.2016.12.020  0.446
2017 Gong J, Cho M, Sy M, Salgia R, Fakih M. Molecular profiling of metastatic colorectal tumors using next-generation sequencing: A single-institution experience. Oncotarget. PMID 28178681 DOI: 10.18632/Oncotarget.15030  0.349
2017 Park JH, Inoue H, Kato T, Zewde M, Miyamoto T, Matsuo Y, Salgia R, Nakamura Y. TOPK (T-LAK cell-originated protein kinase) inhibitor exhibits growth suppressive effect on small cell lung cancer. Cancer Science. PMID 28075524 DOI: 10.1111/Cas.13160  0.475
2017 Yuan Y, Yost SE, Yuan YC, Solomon NM, Mambetsariev I, Pal S, Frankel P, Salgia R, Neuhausen SL, Mortimer J. Genomic mutation-driven metastatic breast cancer therapy: a single center experience. Oncotarget. PMID 28061482 DOI: 10.18632/Oncotarget.14476  0.365
2017 Brand TM, Iida M, Corrigan KL, Braverman CM, Coan JP, Flanigan BG, Stein AP, Salgia R, Rolff J, Kimple RJ, Wheeler DL. The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor. Science Signaling. 10. PMID 28049763 DOI: 10.1126/Scisignal.Aag1064  0.423
2017 Bazhenova L, Gettinger SN, Langer CJ, Salgia R, Gold KA, Rosell R, Shaw AT, Weiss GJ, Haney J, Rivera VM, Kerstein D, Camidge DR. Brigatinib (BRG) in patients (pts) with ALK+ non-small cell lung cancer (NSCLC): Updates from a phase 1/2 trial. Journal of Clinical Oncology. 35: e20682-e20682. DOI: 10.1200/Jco.2017.35.15_Suppl.E20682  0.354
2017 Amanam IU, Gupta R, Mambetsariev I, Koczywas M, Cristea MC, Massarelli E, Reckamp KL, Salgia R. KRAS in non-small cell lung cancer: Single institution experience—What factors are involved? Journal of Clinical Oncology. 35: 11624-11624. DOI: 10.1200/Jco.2017.35.15_Suppl.11624  0.367
2017 Zhang K, Tong TR, Yun X, Nelson R, Isaac N, Salgia R, Raz D. Abstract 4451: Elevated USP22 is a potential therapeutic target for human non-small cell lung cancer Cancer Research. 77: 4451-4451. DOI: 10.1158/1538-7445.Am2017-4451  0.545
2017 Amanam I, Gupta R, Mambetsariev I, Koczywas M, Cristea M, Massarelli E, Reckamp K, Salgia R. KRAS in non-small cell lung cancer Annals of Oncology. 28: v599-v600. DOI: 10.1093/Annonc/Mdx391.013  0.495
2017 Bazhenova L, Gettinger S, Langer C, Salgia R, Gold K, Rosell R, Shaw A, Weiss G, Haney J, Rivera V, Kerstein D, Camidge R. Brigatinib (BRG) in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC): Long-term efficacy and safety results from a phase 1/2 trial Annals of Oncology. 28: v479-v480. DOI: 10.1093/Annonc/Mdx380.046  0.455
2017 Konstantinidis IT, Wen W, Xing Q, Yan J, Shin KM, Kim JY, Raz DJ, Salgia R, Yim JH. Synergistic Anti-Cancer Effect of Baicalein and Metformin against Human Lung Cancer Journal of the American College of Surgeons. 225: S35-S36. DOI: 10.1016/J.Jamcollsurg.2017.07.060  0.44
2016 Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, Shaw AT, Weiss GJ, Tugnait M, Narasimhan NI, Dorer DJ, Kerstein D, Rivera VM, Clackson T, Haluska FG, et al. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. The Lancet. Oncology. PMID 27836716 DOI: 10.1016/S1470-2045(16)30392-8  0.515
2016 Kanteti R, Riehm JJ, Dhanasingh I, Lennon FE, Mirzapoiazova T, Mambetsariev B, Kindler HL, Salgia R. PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma. Scientific Reports. 6: 32992. PMID 27623107 DOI: 10.1038/Srep32992  0.408
2016 Villaflor V, Won B, Nagy R, Banks K, Lanman RB, Talasaz A, Salgia R. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer. Oncotarget. PMID 27602770 DOI: 10.18632/Oncotarget.11801  0.445
2016 Sattler M, Salgia R. MET in the Driver's Seat: Exon 14 Skipping Mutations as Actionable Targets in Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 11: 1381-3. PMID 27565402 DOI: 10.1016/J.Jtho.2016.07.003  0.44
2016 Won B, Mambetsariev I, Salgia R. Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer. Bmc Cancer. 16: 568. PMID 27480287 DOI: 10.1186/S12885-016-2636-Z  0.465
2016 Shi P, Oh YT, Zhang G, Yao W, Yue P, Li Y, Kanteti R, Riehm J, Salgia R, Owonikoko TK, Ramalingam SS, Chen M, Sun SY. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Cancer Letters. PMID 27450722 DOI: 10.1016/J.Canlet.2016.07.021  0.425
2016 Wood K, Hensing T, Salgia R. KRAS in Non-Small-Cell Lung Cancer-Reply. Jama Oncology. PMID 27442777 DOI: 10.1001/Jamaoncol.2016.2347  0.495
2016 Iida M, Bahrar H, Brand TM, Pearson HE, Coan JP, Orbuch RA, Flanigan BG, Swick AD, Prabakaran P, Lantto J, Horak ID, Kragh M, Salgia R, Kimple RJ, Wheeler DL. Targeting the HER family with Pan-HER effectively overcomes resistance to cetuximab. Molecular Cancer Therapeutics. PMID 27422810 DOI: 10.1016/S0959-8049(16)32810-6  0.407
2016 Ali SM, Hensing T, Schrock AB, Allen J, Sanford E, Gowen K, Kulkarni A, He J, Suh JH, Lipson D, Elvin JA, Yelensky R, Chalmers Z, Chmielecki J, Peled N, ... ... Salgia R, et al. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. The Oncologist. PMID 27245569 DOI: 10.1634/Theoncologist.2015-0497  0.417
2016 Rolle CE, Tan YC, Seiwert TY, Vora S, Kanteti R, Hasina R, Carey GB, Surati M, Weichselbaum RR, Lingen MW, Vokes EE, Salgia R. Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma. Oncotarget. PMID 27244893 DOI: 10.18632/Oncotarget.9640  0.337
2016 Rosell R, Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Shaw AT, Narasimhan NI, Dorer DJ, Kerstein D, Camidge DR. 1330: Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive (ALK+) non-small cell lung cancer (NSCLC) in a phase 1/2 trial. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 11: S114. PMID 27198273 DOI: 10.1016/S1556-0864(16)30245-3  0.472
2016 Salgia R. Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma. Expert Review of Molecular Diagnostics. 16: 737-49. PMID 27139190 DOI: 10.1080/14737159.2016.1181545  0.464
2016 Wood K, Hensing T, Malik R, Salgia R. Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review. Jama Oncology. PMID 27100819 DOI: 10.1001/Jamaoncol.2016.0405  0.513
2016 Won B, Carey GB, Tan YH, Bokhary U, Itkonen M, Szeto K, Wallace J, Campbell N, Hensing T, Salgia R. The Chicago Thoracic Oncology Database Consortium: A Multisite Database Initiative. CurēUs. 8: e533. PMID 27092293 DOI: 10.7759/Cureus.533  0.397
2016 Sweis RF, Thomas S, Bank B, Fishkin P, Mooney C, Salgia R. Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer. CurēUs. 8: e513. PMID 27026837 DOI: 10.7759/Cureus.513  0.524
2016 Kanteti R, Batra SK, Lennon FE, Salgia R. FAK and paxillin, two potential targets in pancreatic cancer. Oncotarget. PMID 26980710 DOI: 10.18632/Oncotarget.8040  0.422
2016 Vigneswaran J, Tan YC, Murgu SD, Won BM, Patton KA, Villaflor VM, Hoffman PC, Hensing T, Hogarth DK, Malik R, MacMahon H, Mueller J, Simon CA, Vigneswaran WT, Wigfield CH, ... ... Salgia R, et al. Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation. Oncotarget. PMID 26934441 DOI: 10.18632/Oncotarget.7739  0.413
2016 Lukas RV, Kumthekar P, Rizvi S, Salgia R. Systemic therapies in the treatment of non-small-cell lung cancer brain metastases. Future Oncology (London, England). 12: 1045-58. PMID 26888310 DOI: 10.2217/Fon.16.17  0.417
2016 Inoue H, Kato T, Olugbile S, Tamura K, Chung S, Miyamoto T, Matsuo Y, Salgia R, Nakamura Y, Park JH. Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer. Oncotarget. PMID 26871945 DOI: 10.18632/Oncotarget.7297  0.499
2016 Bunn PA, Minna J, Augustyn A, Gazdar A, Ouadah Y, Krasnow MA, Berns A, Brambilla E, Rekhtman N, Massion PP, Niederst M, Peifer M, Yokota J, Govindan R, Poirier J, ... ... Salgia R, et al. Small Cell Lung Cancer: Can recent advances in biology and molecular biology be translated into improved outcomes? Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 26829312 DOI: 10.1016/J.Jtho.2016.01.012  0.449
2016 Carter CA, Rajan A, Keen C, Szabo E, Khozin S, Thomas A, Brzezniak C, Guha U, Doyle LA, Steinberg SM, Xi L, Raffeld M, Tomita Y, Lee M, Lee S, ... ... Salgia R, et al. Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced non-small cell lung cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. PMID 26802155 DOI: 10.1093/Annonc/Mdw008  0.459
2016 Kanteti R, Dhanasingh I, El-Hashani E, Riehm JJ, Stricker T, Nagy S, Zaborin A, Zaborina O, Biron D, Alverdy JC, Im HK, Siddiqui S, Padilla PA, Salgia R. C. elegans and mutants with chronic nicotine exposure as a novel model of cancer phenotype. Cancer Biology & Therapy. 17: 91-103. PMID 26574927 DOI: 10.1080/15384047.2015.1108495  0.589
2016 Cascone T, Subbiah V, Hess KR, Nelson S, Nilsson MB, Subbiah IM, Ali SM, Carbone DP, Salgia R, Owonikoko TK, Meric-Bernstam F, Doebele RC, Heymach J, trial TCEct. Significant systemic and CNS activity of RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with advanced NSCLC with RET fusion. Journal of Clinical Oncology. 34: 9069-9069. DOI: 10.1200/Jco.2016.34.15_Suppl.9069  0.391
2016 Langer CJ, Gettinger SN, Bazhenova L, Salgia R, Gold KA, Rosell R, Shaw AT, Weiss GJ, Dorer DJ, Rivera VM, Haluska FG, Kerstein D, Camidge DR. Activity and safety of brigatinib (BRG) in patients (pts) with ALK+ non–small cell lung cancer (NSCLC): Phase (ph) 1/2 trial results. Journal of Clinical Oncology. 34: 9057-9057. DOI: 10.1200/Jco.2016.34.15_Suppl.9057  0.369
2016 Shi P, Oh Y, Zhang G, Yao W, Yue P, Kanteti R, Riehm J, Salgia R, Owonikoko T, Ramalingam SS, Chen M, Sun S. Abstract 2105: c-Met hyperactivation is an universal resistance mechanism to both first and third generation EGFR inhibitors Cancer Research. 76: 2105-2105. DOI: 10.1158/1538-7445.Am2016-2105  0.395
2016 Bazhenova L, Gettinger S, Langer C, Salgia R, Gold K, Rosell R, Shaw A, Weiss G, Haney J, Rivera V, Haluska F, Kerstein D, Camidge D. Brigatinib (BRG) in patients (Pts) with anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancer (NSCLC) in a phase 1/2 trial Annals of Oncology. 27: vi418. DOI: 10.1093/Annonc/Mdw383.08  0.489
2015 Fu P, Usatyuk PV, Jacobson J, Cress AE, Garcia JG, Salgia R, Natarajan V. Role played by paxillin and paxillin tyrosine phosphorylation in hepatocyte growth factor/sphingosine-1-phosphate-mediated reactive oxygen species generation, lamellipodia formation, and endothelial barrier function. Pulmonary Circulation. 5: 619-30. PMID 26697169 DOI: 10.1086/683693  0.336
2015 Catenacci DV, Junttila MR, Karrison T, Bahary N, Horiba MN, Nattam SR, Marsh R, Wallace J, Kozloff M, Rajdev L, Cohen D, Wade J, Sleckman B, Lenz HJ, Stiff P, ... ... Salgia R, et al. Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26527777 DOI: 10.1200/Jco.2015.62.8719  0.328
2015 Mirzapoiazova T, Mambetsariev N, Lennon FE, Mambetsariev B, Berlind JE, Salgia R, Singleton PA. HABP2 is a Novel Regulator of Hyaluronan-Mediated Human Lung Cancer Progression. Frontiers in Oncology. 5: 164. PMID 26258071 DOI: 10.3389/Fonc.2015.00164  0.466
2015 Kubic JD, Lui JW, Little EC, Ludvik AE, Konda S, Salgia R, Aplin AE, Lang D. PAX3 and FOXD3 Promote CXCR4 Expression in Melanoma. The Journal of Biological Chemistry. 290: 21901-14. PMID 26205821 DOI: 10.1074/Jbc.M115.670976  0.309
2015 Lennon FE, Cianci GC, Cipriani NA, Hensing TA, Zhang HJ, Chen CT, Murgu SD, Vokes EE, Vannier MW, Salgia R. Lung cancer-a fractal viewpoint. Nature Reviews. Clinical Oncology. PMID 26169924 DOI: 10.1038/Nrclinonc.2015.108  0.425
2015 Lukas RV, Hasan Y, Nicholas MK, Salgia R. ROS1 rearranged non-small cell lung cancer brain metastases respond to low dose radiotherapy. Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia. 22: 1978-9. PMID 26159887 DOI: 10.1016/J.Jocn.2015.04.009  0.416
2015 Lara PN, Longmate J, Mack PC, Kelly K, Socinski MA, Salgia R, Gitlitz B, Li T, Koczywas M, Reckamp KL, Gandara DR. Phase II Study of the AKT inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer who Previously Progressed on Erlotinib. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26106072 DOI: 10.1158/1078-0432.Ccr-14-3281  0.485
2015 Ferguson BD, Carol Tan YH, Kanteti RS, Liu R, Gayed MJ, Vokes EE, Ferguson MK, John Iafrate A, Gill PS, Salgia R. Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer. Scientific Reports. 5: 10641. PMID 26073592 DOI: 10.1038/Srep10641  0.821
2015 Ramalingam S, Goss G, Rosell R, Schmid-Bindert G, Zaric B, Andric Z, Bondarenko I, Komov D, Ceric T, Khuri F, Samarzija M, Felip E, Ciuleanu T, Hirsh V, Wehler T, ... ... Salgia R, et al. A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1). Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 26: 1741-8. PMID 25997818 DOI: 10.1093/Annonc/Mdv220  0.417
2015 Frampton GM, Ali SM, Rosenzweig M, Chmielecki J, Lu X, Bauer TM, Akimov M, Bufill JA, Lee C, Jentz D, Hoover R, Ou SI, Salgia R, Brennan T, Chalmers ZR, et al. Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors. Cancer Discovery. PMID 25971938 DOI: 10.1158/2159-8290.Cd-15-0285  0.418
2015 Zhang H, Wroblewski K, Jiang Y, Penney BC, Appelbaum D, Simon CA, Salgia R, Pu Y. A new PET/CT volumetric prognostic index for non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 89: 43-9. PMID 25936471 DOI: 10.1016/J.Lungcan.2015.03.023  0.401
2015 Fu P, Usatyuk PV, Lele A, Harijith A, Gregorio CC, Garcia JG, Salgia R, Natarajan V. c-Abl mediated tyrosine phosphorylation of paxillin regulates LPS-induced endothelial dysfunction and lung injury. American Journal of Physiology. Lung Cellular and Molecular Physiology. 308: L1025-38. PMID 25795725 DOI: 10.1152/Ajplung.00306.2014  0.327
2015 Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, Pearson HE, Bahrar H, Fowler TL, Bednarz BP, Saha S, Yang D, Gill PS, Lingen MW, Saloura V, ... ... Salgia R, et al. AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2601-12. PMID 25767293 DOI: 10.1158/1078-0432.Ccr-14-2648  0.334
2015 Salgia R. Diagnostic challenges in non-small-cell lung cancer: an integrated medicine approach. Future Oncology (London, England). 11: 489-500. PMID 25675128 DOI: 10.2217/Fon.14.275  0.43
2015 Dikopf A, Wood K, Salgia R. A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients. Expert Opinion On Drug Safety. 14: 485-93. PMID 25659177 DOI: 10.1517/14740338.2015.1007040  0.42
2015 Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, et al. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 10: S1-63. PMID 25535693 DOI: 10.1097/Jto.0000000000000405  0.521
2015 Kendra KL, Plummer R, Salgia R, O'Brien ME, Paul EM, Suttle AB, Compton N, Xu CF, Ottesen LH, Villalona-Calero MA. A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors. Molecular Cancer Therapeutics. 14: 461-9. PMID 25504632 DOI: 10.1158/1535-7163.Mct-14-0431  0.335
2015 Lukas RV, Mata-Machado NA, Nicholas MK, Salgia R, Antic T, Villaflor VM. Leptomeningeal carcinomatosis in esophageal cancer: a case series and systematic review of the literature. Diseases of the Esophagus : Official Journal of the International Society For Diseases of the Esophagus. 28: 772-81. PMID 25142531 DOI: 10.1111/Dote.12276  0.377
2015 Sargis RM, Salgia R. Multiple Endocrine Disruption by the MET/ALK Inhibitor Crizotinib in Patients With Non-small Cell Lung Cancer. American Journal of Clinical Oncology. 38: 442-7. PMID 23934135 DOI: 10.1097/Coc.0B013E3182A46896  0.499
2015 Shah AK, Sachdew V, Taylor-Parker J, Tapan U, Tohme YH, Malinkovich Y, Tran B, Gibbs P, Salgia R, White FM, Parvin J, Bharti A. Effect of DNA-PK dependent phosphorylation of topo-I-S10 on its rate of proteasomal degradation and CPT response. Journal of Clinical Oncology. 33: 606-606. DOI: 10.1200/Jco.2015.33.3_Suppl.606  0.349
2015 Kang Y, LoRusso P, Salgia R, Yen C, Lin C, Ramanathan RK, Kaminker P, Sokolova I, Bhathena A, Wang L, Naumovski L, Strickler JH. Phase I study of ABT-700, an anti-c-Met antibody, in patients (pts) with advanced gastric or esophageal cancer (GEC). Journal of Clinical Oncology. 33: 167-167. DOI: 10.1200/Jco.2015.33.3_Suppl.167  0.357
2015 Camidge DR, Bazhenova L, Salgia R, Langer CJ, Gold KA, Rosell R, Shaw AT, Weiss GJ, Narasimhan NI, Dorer DJ, Rivera VM, Clackson TP, Conlan MG, Kerstein D, Haluska FG, et al. Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK+ non–small cell lung cancer (NSCLC). Journal of Clinical Oncology. 33: 8062-8062. DOI: 10.1200/Jco.2015.33.15_Suppl.8062  0.476
2015 Salgia R, Weaver RW, McCleod M, Stille JR, Yan SB, Roberson S, Hamid O, Polzer J, Flynt A, Raddad E, Spigel DR. Evaluation of CXCR4 expression on tumor and circulating tumor cells (CTCs) as predictive response marker for CXCR4 antagonist LY2510924 in combination with carboplatin-etoposide in extensive-disease small cell lung cancer (ED-SCLC). Journal of Clinical Oncology. 33: 7567-7567. DOI: 10.1200/Jco.2015.33.15_Suppl.7567  0.505
2015 Maron SB, Karrison T, Kanteti R, Rao KA, Gandara DR, Koczywas M, Salgia R, Kindler HL. ARQ 197 in patients with previously-treated malignant mesothelioma (MM): A phase II trial from the University of Chicago Phase II Consortium. Journal of Clinical Oncology. 33: 7511-7511. DOI: 10.1200/Jco.2015.33.15_Suppl.7511  0.316
2015 Frampton GM, Ali SM, Rosenzweig M, Goldman JW, Lee CB, Weiss J, Bufill JA, Salgia R, Jahanzeb M, Konduri K, Forde PM, Morosini D, Ross JS, Ou SI, Yelensky R, et al. Comprehensive genomic profiling (CGP) of advanced cancers to identify MET exon 14 alterations that confer sensitivity to MET inhibitors. Journal of Clinical Oncology. 33: 11007-11007. DOI: 10.1200/Jco.2015.33.15_Suppl.11007  0.368
2015 Tan W, Wilner KD, Lanzalone S, Polli A, Zierhut ML, Nickens D, O'Byrne KJ, Blackhall FH, Shaw AT, Salgia R, Jaime JC, Kim D. Abstract CT117: Evaluation of the effect of crizotinib (CRZ) on the QT interval in patients with ALK-positive non-small cell lung cancer (NSCLC) Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Ct117  0.359
2015 Tan YC, Rolle C, Zhu L, Srivastava MK, Sharma S, Salgia R. Abstract 4361: Efficacy of MET inhibitors in NSCLC with CBL alterations Cancer Research. 75: 4361-4361. DOI: 10.1158/1538-7445.Am2015-4361  0.365
2015 Kerstein D, Gettinger S, Gold K, Langer C, Shaw A, Bazhenova L, Salgia R, Dorer D, Conlan M, Camidge D. Evaluation of Anaplastic Lymphoma Kinase (ALK) Inhibitor Brigatinib [AP26113] in Patients (PTS) with Alk+ Non–Small Cell Lung Cancer (NSCLC) and Brain Metastases Annals of Oncology. 26: i57. DOI: 10.1093/Annonc/Mdv128.06  0.481
2015 Rosell R, Gettinger S, Bazhenova L, Langer C, Salgia R, Gold K, Shaw A, Dorer D, Kerstein D, Camidge D. Phase 1/2 Study of Ap26113 in Patients (PTS) with Advanced Malignancies, Including Anaplastic Lymphoma Kinase (ALK)–Positive Non-Small Cell Lung Cancer (NSCLC): Analysis of Safety and Efficacy at Selected Phase 2 Doses Annals of Oncology. 26: i29. DOI: 10.1093/Annonc/Mdv050.03  0.455
2015 Pietanza M, Spigel D, Bauer T, Ready N, Glisson B, Morgensztern D, Robert F, Salgia R, Kochendorfer M, Patel M, Strickland D, Govindan R, Burris H, Rudin C, Dylla S. 7LBA Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC), in small cell lung cancer (SCLC) European Journal of Cancer. 51: S712. DOI: 10.1016/S0959-8049(16)31931-1  0.431
2015 Camidge D, Bazhenova L, Salgia R, Langer C, Gold K, Rosell R, Shaw A, Weiss G, Dorer D, Rivera V, Conlan M, Kerstein D, Gettinger S. 3061 Assessment of Brigatinib (AP26113) CNS Activity in Patients (Pts) With ALK+ NSCLC and intracranial metastases in a Phase 1/2 Study European Journal of Cancer. 51: S616. DOI: 10.1016/S0959-8049(16)31703-8  0.314
2015 Frampton G, Ali S, Rosenzweig M, Chmielecki J, Bauer T, Akimov M, Peters M, Bufill J, Lee C, Ou I, Salgia R, Yelensky R, Morosini D, Ross J, Philip S, et al. 464 Comprehensive genomic profiling of advanced cancers identifies MET exon 14 alterations that are sensitive to MET inhibitors European Journal of Cancer. 51: S99-S100. DOI: 10.1016/S0959-8049(16)30298-2  0.374
2015 Gettinger S, Bazhenova L, Salgia R, Langer C, Gold K, Rosell R, Shaw A, Weiss G, Narasimhan N, Dorer D, Rivera V, Clackson T, Haluska F, Camidge D. 81: Efficacy and safety of AP26113 in ALK+ non-small cell lung cancer (NSCLC), including patients with brain metastases Lung Cancer. 87: S32. DOI: 10.1016/S0169-5002(15)50080-9  0.456
2014 Spigel DR, Weaver RW, McCleod M, Hamid O, Stille JR, Polzer J, Roberson S, Salgia R. 1472PPHASE II STUDY OF CARBOPLATIN/ETOPOSIDE PLUS LY2510924, A CXCR4 PEPTIDE ANTAGONIST, VERSUS CARBOPLATIN/ETOPOSIDE IN PATIENTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER (SCLC). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv514. PMID 28172401 DOI: 10.1093/Annonc/Mdu355.10  0.371
2014 Shaw A, Ou SI, Bang Y, Camidge R, Solomon B, Salgia R, Riely GJ, Varella-Garcia M, Shapiro G, Costa D, Doebele R, Le LP, Zheng Z, Stephenson P, Shreeve SM, et al. 1299PCLINICAL ACTIVITY OF CRIZOTINIB IN ROS1-REARRANGED NON-SMALL CELL LUNG CANCER. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv458. PMID 28172052 DOI: 10.1093/Annonc/Mdu349.78  0.436
2014 Gettinger S, Bazhenova L, Salgia R, Langer C, Gold K, Rosell R, Shaw A, Weiss GJ, Narasimhan NI, Dorer DJ, Rivera VM, Clackson T, Haluska FG, Camidge R. 1292PALK INHIBITOR AP26113 IN PATIENTS WITH ADVANCED MALIGNANCIES, INCLUDING ALK+ NON-SMALL CELL LUNG CANCER (NSCLC): UPDATED EFFICACY AND SAFETY DATA. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv455. PMID 28172024 DOI: 10.1093/Annonc/Mdu349.71  0.359
2014 West AH, Yamada SD, MacMahon H, Acharya SS, Ali SM, He J, Lukas RV, Miller VA, Salgia R. Unique metastases of ALK mutated lung cancer activated to the adnexa of the uterus. Case Reports in Clinical Pathology. 1: 151-154. PMID 25541622 DOI: 10.5430/Crcp.V1N2P151  0.506
2014 Ferguson BD, Tretiakova MS, Lingen MW, Gill PS, Salgia R. Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition. Growth Factors (Chur, Switzerland). 32: 202-6. PMID 25391996 DOI: 10.3109/08977194.2014.980904  0.786
2014 Iida M, Brand TM, Starr MM, Huppert EJ, Luthar N, Bahrar H, Coan JP, Pearson HE, Salgia R, Wheeler DL. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy. Molecular Cancer. 13: 242. PMID 25344208 DOI: 10.1186/1476-4598-13-242  0.409
2014 Jardim DL, Tang C, Gagliato Dde M, Falchook GS, Hess K, Janku F, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, Holla V, Li MM, Roy-Chowdhuri S, Luthra R, ... Salgia R, et al. Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 6336-45. PMID 25326232 DOI: 10.1158/1078-0432.Ccr-14-1293  0.345
2014 Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa DB, Doebele RC, Le LP, Zheng Z, Tan W, Stephenson P, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. The New England Journal of Medicine. 371: 1963-71. PMID 25264305 DOI: 10.1056/Nejmoa1406766  0.469
2014 Kanteti R, Dhanasingh I, Kawada I, Lennon FE, Arif Q, Bueno R, Hasina R, Husain AN, Vigneswaran W, Seiwert T, Kindler HL, Salgia R. MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma. Plos One. 9: e105919. PMID 25221930 DOI: 10.1371/Journal.Pone.0105919  0.384
2014 Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Luthar N, Toulany M, Gill PS, Salgia R, Kimple RJ, Wheeler DL. AXL mediates resistance to cetuximab therapy. Cancer Research. 74: 5152-64. PMID 25136066 DOI: 10.1158/0008-5472.Can-14-0294  0.456
2014 Smieliauskas F, MacMahon H, Salgia R, Shih YC. Geographic variation in radiologist capacity and widespread implementation of lung cancer CT screening. Journal of Medical Screening. 21: 207-15. PMID 25118160 DOI: 10.1177/0969141314548055  0.347
2014 Lukas RV, Lesniak MS, Salgia R. Brain metastases in non-small-cell lung cancer: better outcomes through current therapies and utilization of molecularly targeted approaches. Cns Oncology. 3: 61-75. PMID 25054901 DOI: 10.2217/Cns.13.66  0.426
2014 Lennon FE, Mirzapoiazova T, Mambetsariev N, Mambetsariev B, Salgia R, Singleton PA. Transactivation of the receptor-tyrosine kinase ephrin receptor A2 is required for the low molecular weight hyaluronan-mediated angiogenesis that is implicated in tumor progression. The Journal of Biological Chemistry. 289: 24043-58. PMID 25023279 DOI: 10.1074/Jbc.M114.554766  0.37
2014 Singleton PA, Mirzapoiazova T, Hasina R, Salgia R, Moss J. Increased μ-opioid receptor expression in metastatic lung cancer. British Journal of Anaesthesia. 113: i103-8. PMID 24920011 DOI: 10.1093/Bja/Aeu165  0.491
2014 Shtivelman E, Hensing T, Simon GR, Dennis PA, Otterson GA, Bueno R, Salgia R. Molecular pathways and therapeutic targets in lung cancer. Oncotarget. 5: 1392-433. PMID 24722523 DOI: 10.18632/Oncotarget.1891  0.507
2014 Salgia R. Fibroblast growth factor signaling and inhibition in non-small cell lung cancer and their role in squamous cell tumors. Cancer Medicine. 3: 681-92. PMID 24711160 DOI: 10.1002/Cam4.238  0.482
2014 Lennon FE, Mirzapoiazova T, Mambetsariev B, Poroyko VA, Salgia R, Moss J, Singleton PA. The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer. Plos One. 9: e91577. PMID 24662916 DOI: 10.1371/Journal.Pone.0091577  0.441
2014 Lennon FE, Salgia R. Mitochondrial dynamics: biology and therapy in lung cancer. Expert Opinion On Investigational Drugs. 23: 675-92. PMID 24654596 DOI: 10.1517/13543784.2014.899350  0.402
2014 Brand TM, Iida M, Dunn EF, Luthar N, Kostopoulos KT, Corrigan KL, Wleklinski MJ, Yang D, Wisinski KB, Salgia R, Wheeler DL. Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer. Molecular Cancer Therapeutics. 13: 1356-68. PMID 24634415 DOI: 10.1158/1535-7163.Mct-13-1021  0.442
2014 Usatyuk PV, Fu P, Mohan V, Epshtein Y, Jacobson JR, Gomez-Cambronero J, Wary KK, Bindokas V, Dudek SM, Salgia R, Garcia JG, Natarajan V. Role of c-Met/phosphatidylinositol 3-kinase (PI3k)/Akt signaling in hepatocyte growth factor (HGF)-mediated lamellipodia formation, reactive oxygen species (ROS) generation, and motility of lung endothelial cells. The Journal of Biological Chemistry. 289: 13476-91. PMID 24634221 DOI: 10.1074/Jbc.M113.527556  0.386
2014 Kanteti R, El-Hashani E, Dhanasingh I, Tretiakova M, Husain AN, Sharma S, Sharma J, Vokes EE, Salgia R. Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer. Bmc Cancer. 14: 185. PMID 24628993 DOI: 10.1186/1471-2407-14-185  0.523
2014 Gong J, Wang Z, Polejaeva I, Salgia R, Kao CM, Chen CT, Chen G, Chen L. Activating the expression of human K-rasG12D stimulates oncogenic transformation in transgenic goat fetal fibroblast cells. Plos One. 9: e90059. PMID 24594684 DOI: 10.1371/Journal.Pone.0090059  0.403
2014 Salgia R, Patel P, Bothos J, Yu W, Eppler S, Hegde P, Bai S, Kaur S, Nijem I, Catenacci DV, Peterson A, Ratain MJ, Polite B, Mehnert JM, Moss RA. Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1666-75. PMID 24493831 DOI: 10.1158/1078-0432.Ccr-13-2070  0.328
2014 Maitland ML, Levine MR, Lacouture ME, Wroblewski KE, Chung CH, Gordon IO, Szeto L, Ratko G, Soltani K, Kozloff MF, Hoffman PC, Salgia R, Carbone DP, Karrison TG, Vokes EE. Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer. Bmc Cancer. 14: 5. PMID 24386952 DOI: 10.1186/1471-2407-14-5  0.47
2014 Rolle CE, Kanteti R, Surati M, Nandi S, Dhanasingh I, Yala S, Tretiakova M, Arif Q, Hembrough T, Brand TM, Wheeler DL, Husain AN, Vokes EE, Bharti A, Salgia R. Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer. Molecular Cancer Therapeutics. 13: 576-84. PMID 24327519 DOI: 10.1158/1535-7163.Mct-13-0109  0.433
2014 Kawada I, Hasina R, Arif Q, Mueller J, Smithberger E, Husain AN, Vokes EE, Salgia R. Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer. Cancer Research. 74: 884-95. PMID 24305878 DOI: 10.1158/0008-5472.Can-12-3583  0.539
2014 Hensing T, Chawla A, Batra R, Salgia R. A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization. Advances in Experimental Medicine and Biology. 799: 85-117. PMID 24292963 DOI: 10.1007/978-1-4614-8778-4_5  0.513
2014 Puri N, Pitman RT, Mulnix RE, Erickson T, Iness AN, Vitali C, Zhao Y, Salgia R. Non-small cell lung cancer is susceptible to induction of DNA damage responses and inhibition of angiogenesis by telomere overhang oligonucleotides. Cancer Letters. 343: 14-23. PMID 24041868 DOI: 10.1016/J.Canlet.2013.09.010  0.423
2014 Villaflor VM, Wheeler D, Iida M, Vidwans S, Turski M, Brand TM, Won B, Ferguson MK, Patti MG, Posner M, Waxman I, Gordon G, Vokes EE, Salgia R. Genetic alterations in esophageal cancers: Detection by next-generation sequencing and potential for therapeutic targets. Journal of Clinical Oncology. 32: e22065-e22065. DOI: 10.1200/Jco.2014.32.15_Suppl.E22065  0.424
2014 Feldman R, Xiu J, Salgia R. Tumor Biomarker Evaluation of 6785 Patients for Combination Treatment Strategies in NSCLC International Journal of Radiation Oncology*Biology*Physics. 90: S71. DOI: 10.1200/Jco.2014.32.15_Suppl.E19012  0.471
2014 Ali SM, Ou SI, He J, Peled N, Chmielecki J, Pinder MC, Palma NA, Akerley WL, Wang K, Molina JR, Ross JS, Yelensky R, Frampton GM, Bazhenova L, Palmer GA, ... ... Salgia R, et al. Identifying ALK rearrangements that are not detected by FISH with targeted next-generation sequencing of lung carcinoma. Journal of Clinical Oncology. 32: 8049-8049. DOI: 10.1200/Jco.2014.32.15_Suppl.8049  0.424
2014 Gettinger SN, Bazhenova L, Salgia R, Langer CJ, Gold KA, Rosell R, Shaw AT, Weiss GJ, Narasimhan NI, Dorer DJ, Rivera VM, Clackson T, Haluska FG, Camidge DR. Updated efficacy and safety of the ALK inhibitor AP26113 in patients (pts) with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 32: 8047-8047. DOI: 10.1200/Jco.2014.32.15_Suppl.8047  0.37
2014 Lara P, Longmate J, Mack PC, Kelly K, Socinski MA, Salgia R, Gitlitz BJ, Li T, Koczywas M, Reckamp KL, Gandara DR. Phase II study of the AKT inhibitor MK-2206 plus erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC) who progressed on prior erlotinib: A California Cancer Consortium Phase II trial (NCI 8698). Journal of Clinical Oncology. 32: 8015-8015. DOI: 10.1200/Jco.2014.32.15_Suppl.8015  0.411
2014 Hasina R, Kawada I, Arif Q, Mueller J, Husain AN, Vokes EE, Salgia R. Abstract LB-239: Inhibition of MET/RON in lung cancer Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-239  0.518
2014 Brand TM, Iida M, Corrigan KL, Luthar N, Hornung M, Toulany M, Gill P, Salgia R, Wheeler DL. Abstract LB-215: The TAM family of receptor tyrosine kinases play a role in acquired resistance to cetuximab Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-215  0.447
2014 Tan Y, Rolle C, Zhu L, Srivastava M, Sharma S, Salgia R. Efficacy of MET Inhibitors in NSCLC With CBL Alterations International Journal of Radiation Oncology*Biology*Physics. 90: S53-S54. DOI: 10.1016/J.Ijrobp.2014.08.254  0.368
2014 West A, Yamada SD, Macmahon H, Ali SM, Stephens P, Miller VA, Salgia R. Unique pattern of metastasis to the adenexa in ALK rearranged non-small cell lung cancer. Journal of Clinical Oncology. 32: e19036-e19036. DOI: 10.1016/J.Ijrobp.2014.08.250  0.485
2014 West A, Yamada S, MacMahon H, Ali S, Lukas R, Salgia R. Unique Pattern of Metastasis to the Adnexa in ALK Rearranged Non-Small Cell Lung Cancer International Journal of Radiation Oncology*Biology*Physics. 90: S52. DOI: 10.1016/j.ijrobp.2014.08.250  0.384
2013 Hasina R, Surati M, Kawada I, Arif Q, Carey GB, Kanteti R, Husain AN, Ferguson MK, Vokes EE, Villaflor VM, Salgia R. O-6-methylguanine-deoxyribonucleic acid methyltransferase methylation enhances response to temozolomide treatment in esophageal cancer. Journal of Carcinogenesis. 12: 20. PMID 24319345 DOI: 10.4103/1477-3163.120632  0.387
2013 Hensing TA, Salgia R. Molecular biomarkers for future screening of lung cancer. Journal of Surgical Oncology. 108: 327-33. PMID 23893423 DOI: 10.1002/Jso.23382  0.424
2013 Ferguson BD, Liu R, Rolle CE, Tan YH, Krasnoperov V, Kanteti R, Tretiakova MS, Cervantes GM, Hasina R, Hseu RD, Iafrate AJ, Karrison T, Ferguson MK, Husain AN, Faoro L, ... ... Salgia R, et al. The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target. Plos One. 8: e67668. PMID 23844053 DOI: 10.1371/Journal.Pone.0067668  0.831
2013 Shieh JM, Tang YA, Yang TH, Chen CY, Hsu HS, Tan YH, Salgia R, Wang YC. Lack of association of C-Met-N375S sequence variant with lung cancer susceptibility and prognosis. International Journal of Medical Sciences. 10: 988-94. PMID 23801885 DOI: 10.7150/Ijms.5944  0.412
2013 Kawada I, Hasina R, Lennon FE, Bindokas VP, Usatyuk P, Tan YH, Krishnaswamy S, Arif Q, Carey G, Hseu RD, Robinson M, Tretiakova M, Brand TM, Iida M, Ferguson MK, ... ... Salgia R, et al. Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: relevance to lung cancer. Cancer Biology & Therapy. 14: 679-91. PMID 23792636 DOI: 10.4161/Cbt.25091  0.484
2013 Lukas RV, Vigneswaran J, Salgia R. Etoposide and temozolomide in combination for the treatment of progressive small-cell lung cancer central nervous system metastases: two cases. Tumori. 99: e73-6. PMID 23748834 DOI: 10.1700/1283.14212  0.49
2013 Liu R, Ferguson BD, Zhou Y, Naga K, Salgia R, Gill PS, Krasnoperov V. EphB4 as a therapeutic target in mesothelioma. Bmc Cancer. 13: 269. PMID 23721559 DOI: 10.1186/1471-2407-13-269  0.769
2013 Traynor AM, Weigel TL, Oettel KR, Yang DT, Zhang C, Kim K, Salgia R, Iida M, Brand TM, Hoang T, Campbell TC, Hernan HR, Wheeler DL. Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 81: 138-41. PMID 23628526 DOI: 10.1016/J.Lungcan.2013.03.020  0.489
2013 Zhao Y, Zhao J, Mialki RK, Wei J, Spannhake EW, Salgia R, Natarajan V. Lipopolysaccharide-induced phosphorylation of c-Met tyrosine residue 1003 regulates c-Met intracellular trafficking and lung epithelial barrier function. American Journal of Physiology. Lung Cellular and Molecular Physiology. 305: L56-63. PMID 23624790 DOI: 10.1152/Ajplung.00417.2012  0.35
2013 Villaflor VM, Salgia R. Targeted agents in non-small cell lung cancer therapy: What is there on the horizon? Journal of Carcinogenesis. 12: 7. PMID 23599689 DOI: 10.4103/1477-3163.109253  0.477
2013 Socinski MA, Goldman J, El-Hariry I, Koczywas M, Vukovic V, Horn L, Paschold E, Salgia R, West H, Sequist LV, Bonomi P, Brahmer J, Chen LC, Sandler A, Belani CP, et al. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 3068-77. PMID 23553849 DOI: 10.1158/1078-0432.Ccr-12-3381  0.481
2013 Brägelmann J, Dagogo-Jack I, El Dinali M, Stricker T, Brown CD, Zuo Z, Khattri A, Keck M, McNerney ME, Longnecker R, Bieging K, Kocherginsky M, Alexander K, Salgia R, Lingen MW, et al. Oral cavity tumors in younger patients show a poor prognosis and do not contain viral RNA. Oral Oncology. 49: 525-33. PMID 23490885 DOI: 10.1016/J.Oraloncology.2013.02.003  0.342
2013 Sadiq AA, Salgia R. MET as a possible target for non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 1089-96. PMID 23401458 DOI: 10.1200/Jco.2012.43.9422  0.529
2013 Vokes EE, Salgia R, Karrison TG. Evidence-based role of bevacizumab in non-small cell lung cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 24: 6-9. PMID 23251009 DOI: 10.1093/Annonc/Mds608  0.492
2013 Ephstein Y, Singleton PA, Chen W, Wang L, Salgia R, Kanteti P, Dudek SM, Garcia JG, Jacobson JR. Critical role of S1PR1 and integrin β4 in HGF/c-Met-mediated increases in vascular integrity. The Journal of Biological Chemistry. 288: 2191-200. PMID 23212923 DOI: 10.1074/Jbc.M112.404780  0.314
2013 Hasina R, Mollberg N, Kawada I, Mutreja K, Kanade G, Yala S, Surati M, Liu R, Li X, Zhou Y, Ferguson BD, Nallasura V, Cohen KS, Hyjek E, Mueller J, ... ... Salgia R, et al. Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers. Cancer Research. 73: 184-94. PMID 23100466 DOI: 10.1158/0008-5472.Can-12-0915  0.815
2013 Hensing TA, Karrison T, Garmey EG, Hennessy MG, Salgia R. Randomized phase II study of IV topotecan versus CRLX101 in the second-line treatment of recurrent extensive-stage small cell lung cancer (ES-SCLC). Journal of Clinical Oncology. 31: TPS7610-TPS7610. DOI: 10.1200/Jco.2013.31.15_Suppl.Tps7610  0.362
2013 Hembrough TA, Liao W, Thyparambil S, Erickson HS, Carey G, Guiel T, Heaton RB, Krizman D, Wistuba II, Salgia R, Burrows J. Development and clinical validation of an adeno/squamous multiplexed diagnostic assay for NSCLC. Journal of Clinical Oncology. 31. DOI: 10.1200/Jco.2013.31.15_Suppl.E19057  0.313
2013 Ou SI, Bang Y, Camidge DR, Riely GJ, Salgia R, Shapiro G, Solomon BJ, Engelman JA, Kwak EL, Clark JW, Tye L, Wilner KD, Stephenson P, Varella-Garcia M, Bergethon K, et al. Efficacy and safety of crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 31: 8032-8032. DOI: 10.1200/Jco.2013.31.15_Suppl.8032  0.41
2013 Camidge DR, Bazhenova L, Salgia R, Weiss GJ, Langer CJ, Shaw AT, Narasimhan NI, Dorer DJ, Rivera VM, Zhang J, Clackson T, Haluska FG, Gettinger SN. First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: Updated results. Journal of Clinical Oncology. 31: 8031-8031. DOI: 10.1200/Jco.2013.31.15_Suppl.8031  0.367
2013 Carter CA, Rajan A, Szabo E, Khozin S, Thomas A, Brzezniak CE, Guha U, Doyle LA, Keen C, Steinberg SM, Xi L, Raffeld M, Reckamp KL, Koehler S, Gitlitz BJ, ... Salgia R, et al. Two parallel randomized phase II studies of selumetinib (S) and erlotinib (E) in advanced non-small cell lung cancer selected by KRAS mutations. Journal of Clinical Oncology. 31: 8026-8026. DOI: 10.1200/Jco.2013.31.15_Suppl.8026  0.371
2013 Ou SI, Kim D, Camidge R, Riely G, Salgia R, Shapiro G, Clark J, Tye L, Iafrate A, Shaw A. Crizotinib Treatment in Patients (PTS) with Advanced ROS1-Rearranged Non-Small Cell Lung Cancer (NSCLC) Annals of Oncology. 24: ix43. DOI: 10.1093/Annonc/Mdt459.54  0.488
2013 Morales La Madrid A, Campbell N, Smith S, Cohn SL, Salgia R. Erratum to: Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin’s lymphoma, and neuroblastoma Targeted Oncology. 8: 301-301. DOI: 10.1007/s11523-013-0291-8  0.385
2012 Srivastava MK, Zhu L, Harris-White M, Huang M, St John M, Lee JM, Salgia R, Cameron RB, Strieter R, Dubinett S, Sharma S. Targeting myeloid-derived suppressor cells augments antitumor activity against lung cancer. Immunotargets and Therapy. 2012: 7-12. PMID 24791250 DOI: 10.2147/ITT.S32617  0.333
2012 Lukas RV, Nicholas MK, Villaflor V, Hoffman PC, Salgia R. Temozolomide and/or Erlotinib in the Treatment of Lung Cancer Patients With Progressive Central Nervous System Metastases. Journal of Neurology Research. 2: 1-9. PMID 23504695 DOI: 10.4021/Jnr85W  0.437
2012 Sharma S, Dubinett S, Salgia R. CD14(+)S100A9(+) myeloid-derived suppressor cells portend decreased survival in patients with advanced lung cancer. American Journal of Respiratory and Critical Care Medicine. 186: 940-1. PMID 23155211 DOI: 10.1164/Rccm.201209-1597Ed  0.441
2012 Carey GB, Kazantsev S, Surati M, Rolle CE, Kanteti A, Sadiq A, Bahroos N, Raumann B, Madduri R, Dave P, Starkey A, Hensing T, Husain AN, Vokes EE, Vigneswaran W, ... ... Salgia R, et al. Utilisation of a thoracic oncology database to capture radiological and pathological images for evaluation of response to chemotherapy in patients with malignant pleural mesothelioma. Bmj Open. 2. PMID 23103606 DOI: 10.1136/Bmjopen-2012-001620  0.333
2012 Kalari S, Moolky N, Pendyala S, Berdyshev EV, Rolle C, Kanteti R, Kanteti A, Ma W, He D, Husain AN, Kindler HL, Kanteti P, Salgia R, Natarajan V. Sphingosine kinase 1 is required for mesothelioma cell proliferation: role of histone acetylation. Plos One. 7: e45330. PMID 23028939 DOI: 10.1371/Journal.Pone.0045330  0.389
2012 Morales La Madrid A, La Madrid AM, Campbell N, Smith S, Cohn SL, Salgia R. Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma. Targeted Oncology. 7: 199-210. PMID 22968692 DOI: 10.1007/S11523-012-0227-8  0.515
2012 Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW, Salgia R, Fidias P, Engelman JA, Gandhi L, Jänne PA, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. The Lancet. Oncology. 13: 1011-9. PMID 22954507 DOI: 10.1016/S1470-2045(12)70344-3  0.49
2012 Pietanza MC, Gadgeel SM, Dowlati A, Lynch TJ, Salgia R, Rowland KM, Wertheim MS, Price KA, Riely GJ, Azzoli CG, Miller VA, Krug LM, Kris MG, Beumer JH, Tonda M, et al. Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 856-65. PMID 22722787 DOI: 10.1097/Jto.0B013E31824C943F  0.468
2012 Jaklitsch MT, Jacobson FL, Austin JH, Field JK, Jett JR, Keshavjee S, MacMahon H, Mulshine JL, Munden RF, Salgia R, Strauss GM, Swanson SJ, Travis WD, Sugarbaker DJ. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. The Journal of Thoracic and Cardiovascular Surgery. 144: 33-8. PMID 22710039 DOI: 10.1016/J.Jtcvs.2012.05.060  0.43
2012 Jacobson FL, Austin JH, Field JK, Jett JR, Keshavjee S, MacMahon H, Mulshine JL, Munden RF, Salgia R, Strauss GM, Sugarbaker DJ, Swanson SJ, Travis WD, Jaklitsch MT. Development of The American Association for Thoracic Surgery guidelines for low-dose computed tomography scans to screen for lung cancer in North America: recommendations of The American Association for Thoracic Surgery Task Force for Lung Cancer Screening and Surveillance. The Journal of Thoracic and Cardiovascular Surgery. 144: 25-32. PMID 22710038 DOI: 10.1016/J.Jtcvs.2012.05.059  0.375
2012 Lo FY, Chang JW, Chang IS, Chen YJ, Hsu HS, Huang SF, Tsai FY, Jiang SS, Kanteti R, Nandi S, Salgia R, Wang YC. The database of chromosome imbalance regions and genes resided in lung cancer from Asian and Caucasian identified by array-comparative genomic hybridization. Bmc Cancer. 12: 235. PMID 22691236 DOI: 10.1186/1471-2407-12-235  0.361
2012 Kanteti R, Krishnaswamy S, Catenacci D, Tan YH, EL-Hashani E, Cervantes G, Husain AN, Tretiakova M, Vokes EE, Huet H, Salgia R. Differential expression of RON in small and non-small cell lung cancers. Genes, Chromosomes & Cancer. 51: 841-51. PMID 22585712 DOI: 10.1002/Gcc.21968  0.52
2012 West L, Vidwans SJ, Campbell NP, Shrager J, Simon GR, Bueno R, Dennis PA, Otterson GA, Salgia R. A novel classification of lung cancer into molecular subtypes. Plos One. 7: e31906. PMID 22363766 DOI: 10.1371/Journal.Pone.0031906  0.483
2012 Lennon FE, Mirzapoiazova T, Mambetsariev B, Salgia R, Moss J, Singleton PA. Overexpression of the μ-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis. Anesthesiology. 116: 857-67. PMID 22343475 DOI: 10.1097/Aln.0B013E31824Babe2  0.515
2012 Chiappori AA, Schreeder MT, Moezi MM, Stephenson JJ, Blakely J, Salgia R, Chu QS, Ross HJ, Subramaniam DS, Schnyder J, Berger MS. A phase i trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer British Journal of Cancer. 106: 839-845. PMID 22333598 DOI: 10.1038/Bjc.2012.21  0.317
2012 Rehman J, Zhang HJ, Toth PT, Zhang Y, Marsboom G, Hong Z, Salgia R, Husain AN, Wietholt C, Archer SL. Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 26: 2175-86. PMID 22321727 DOI: 10.1096/Fj.11-196543  0.427
2012 Hasselle MD, Haraf DJ, Rusthoven KE, Golden DW, Salgia R, Villaflor VM, Shah N, Hoffman PC, Chmura SJ, Connell PP, Vokes EE, Weichselbaum RR, Salama JK. Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 376-81. PMID 22198429 DOI: 10.1097/Jto.0B013E31824166A5  0.453
2012 Doçi CL, Mankame TP, Langerman A, Ostler KR, Kanteti R, Best T, Onel K, Godley LA, Salgia R, Lingen MW. Characterization of NOL7 gene point mutations, promoter methylation, and protein expression in cervical cancer. International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists. 31: 15-24. PMID 22123719 DOI: 10.1097/Pgp.0B013E318220Ba16  0.373
2012 Cohen EE, Subramanian J, Gao F, Szeto L, Kozloff M, Faoro L, Karrison T, Salgia R, Govindan R, Vokes EE. Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial. Clinical Lung Cancer. 13: 123-8. PMID 22100149 DOI: 10.1016/J.Cllc.2011.10.001  0.488
2012 Puri N, Salgia R. Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer. Journal of Carcinogenesis. 7: 9. PMID 19240370 DOI: 10.4103/1477-3163.44372  0.527
2012 Salgia R. Stamp out lung cancer. Journal of Carcinogenesis. 7: 7. PMID 19008566 DOI: 10.4103/1477-3163.44016  0.451
2012 Ganti AK, Kaur S, West WW, Dhangada Majhi P, Lakshmanan I, Smith L, Rolle CE, Carey G, Sharma P, Salgia R, Batra S. MUC4 expression in non-small cell lung cancer. Journal of Clinical Oncology. 30: e17549-e17549. DOI: 10.1200/Jco.2012.30.15_Suppl.E17549  0.418
2012 Scagliotti G, Kim D, Shaw AT, Ou SI, Riely GJ, Gettinger SN, Besse B, Thomas M, Salgia R, Wilner KD, Bartlett CH, Polli A, Gandara DR. A large retrospective analysis of the activity of pemetrexed (PEM) in patients (pts) with ALK-positive (ALK+) non-small cell lung cancer (NSCLC) prior to crizotinib (CRIZ). Journal of Clinical Oncology. 30: 7599-7599. DOI: 10.1200/Jco.2012.30.15_Suppl.7599  0.338
2012 Kim D, Ahn M, Shi Y, De Pas TM, Yang P, Riely GJ, Crinò L, Evans TL, Liu X, Han J, Salgia R, Moro-Sibilot D, Ou SI, Gettinger SN, Wu YL, et al. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 30: 7533-7533. DOI: 10.1200/Jco.2012.30.15_Suppl.7533  0.377
2012 Shaw AT, Camidge DR, Engelman JA, Solomon BJ, Kwak EL, Clark JW, Salgia R, Shapiro G, Bang Y, Tan W, Tye L, Wilner KD, Stephenson P, Varella-Garcia M, Bergethon K, et al. Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. Journal of Clinical Oncology. 30: 7508-7508. DOI: 10.1200/Jco.2012.30.15_Suppl.7508  0.454
2012 Lennnon FE, Mirzapoiazova T, Mambetsariev B, Salgia R, Moss J, Singleton PA. Abstract 2232: Overexpression of the mu opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth and metastasis Cancer Research. 72: 2232-2232. DOI: 10.1158/1538-7445.Am2012-2232  0.52
2012 Hasina R, Mutreja K, Kawada I, Kanteti R, Arif Q, Liu R, Li X, Zhou Y, Hyjek E, Lingen MW, Mueller J, Waxman I, Villaflor V, Ferguson M, Vokes EE, ... ... Salgia R, et al. Abstract 1861: EPHB4 as a potential therapeutic target for esophageal cancer Cancer Research. 72: 1861-1861. DOI: 10.1158/1538-7445.Am2012-1861  0.465
2012 Salgia R, Nallasura, Pang H, Rolle C, Richards W, Hodgson L, Arif Q, Husain A, Kratzke R, Vokes E. An Interim Report Of CALGB 150607: Expression And Mutational Status Of c-MET, HGF, EGFR, KRAS, p53, c-CBL, And E-cadherin In Resected Lung Adenocarcinoma Specimens Journal of Thoracic Oncology. DOI: 10.1097/Jto.0B013E318269Fc07  0.384
2012 Singleton P, Lennon F, Mirzapoiazova T, Mambetsariev B, Poroyko V, Salgia R, Moss J. 390 Methylnaltrexone Inhibits Opioid- and Growth Factor-Induced Human Lung Cancer Proliferation, Migration and Epithelial Mesenchymal Transition (EMT) European Journal of Cancer. 48: 119. DOI: 10.1016/S0959-8049(12)72188-3  0.394
2012 Blackhall F, Evans T, Han J, Salgia R, Moro-Sibilot D, Gettinger S, Crino L, Wilner K, Reisman A, Iyer S. Impact of Crizotinib Treatment on Patient-Reported Symptoms and Quality of Life (QOL) in Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC) Annals of Oncology. 23: ix403. DOI: 10.1016/S0923-7534(20)33882-5  0.379
2012 Gettinger S, Weiss G, Salgia R, Bazhenova L, Narasimhan N, Dorer D, Rivera V, Zhang J, Clackson T, Haluska F, Shaw A, Camidge D. A First-In-Human Dose-Finding Study of the Alk/Egfr Inhibitor AP26113 in Patients with Advanced Malignancies Annals of Oncology. 23: ix152. DOI: 10.1016/S0923-7534(20)33005-2  0.406
2012 Scagliotti GV, Kim D-, Shaw AT, Ou S-I, Riely GJ, Gettinger SN, Besse B, Thomas M, Salgia R, Wilner K, Bartlett CH, Polli A, Gandara DR. A Large Retrospective Analysis of the Activity of Pemetrexed (PEM) in Patients (Patients) with ALK+ NSCLC Before Crizotinib (CRIZ) Annals of Oncology. 23. DOI: 10.1016/S0923-7534(20)32007-X  0.327
2011 Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Iafrate AJ, Shapiro G, Costa DB, Butaney M, Ou SI, Maki RG, Bang Y, Varella-Garcia M, Salgia R, Wilner KD, Kulig K, et al. Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 7507. PMID 28023300 DOI: 10.1200/Jco.2011.29.15_Suppl.7507  0.462
2011 Camidge DR, Bang Y, Kwak EL, Shaw AT, Iafrate AJ, Maki RG, Solomon BJ, Ou SI, Salgia R, Wilner KD, Costa DB, Shapiro G, LoRusso P, Stephenson P, Tang Y, et al. Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2501. PMID 28022383 DOI: 10.1200/Jco.2011.29.15_Suppl.2501  0.475
2011 Lennerz JK, Kwak EL, Michael M, Fox SB, Ackerman A, Bergethon K, Lauwers GY, Christensen JG, Wilner KD, Haber DA, Salgia R, Bang Y, Clark JW, Solomon BJ, Iafrate AJ. Identification of a small and lethal subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib by MET amplification. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4130. PMID 28021188 DOI: 10.1200/Jco.2011.29.15_Suppl.4130  0.425
2011 Nwizu T, Kanteti R, Kawada I, Rolle C, Vokes EE, Salgia R. Crizotinib (PF02341066) as a ALK /MET inhibitor- Special Emphasis as a Therapeutic Drug Against Lung Cancer. Drugs of the Future. 36: 91-99. PMID 26412935 DOI: 10.1358/Dof.2011.036.02.1584112  0.495
2011 Catenacci DV, Henderson L, Xiao SY, Patel P, Yauch RL, Hegde P, Zha J, Pandita A, Peterson A, Salgia R. Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discovery. 1: 573-9. PMID 22389872 DOI: 10.1158/2159-8290.Cd-11-0175  0.386
2011 Tretiakova M, Salama AK, Karrison T, Ferguson MK, Husain AN, Vokes EE, Salgia R. MET and phosphorylated MET as potential biomarkers in lung cancer. Journal of Environmental Pathology, Toxicology and Oncology : Official Organ of the International Society For Environmental Toxicology and Cancer. 30: 341-54. PMID 22181983 DOI: 10.1615/Jenvironpatholtoxicoloncol.V30.I4.70  0.501
2011 Surati M, Patel P, Peterson A, Salgia R. Role of MetMAb (OA-5D5) in c-MET active lung malignancies. Expert Opinion On Biological Therapy. 11: 1655-62. PMID 22047509 DOI: 10.1517/14712598.2011.626762  0.385
2011 Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Bergethon K, Lauwers GY, Christensen JG, Wilner KD, Haber DA, Salgia R, Bang YJ, Clark JW, Solomon BJ, Iafrate AJ. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4803-10. PMID 22042947 DOI: 10.1200/Jco.2011.35.4928  0.425
2011 Sadiq AA, Geynisman DM, Salgia R. Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: S1810-1. PMID 22005540 DOI: 10.1097/01.Jto.0000407568.45147.43  0.494
2011 Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, Shapiro GI, Costa DB, Ou SH, Butaney M, Salgia R, Maki RG, Varella-Garcia M, Doebele RC, Bang YJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. The Lancet. Oncology. 12: 1004-12. PMID 21933749 DOI: 10.1016/S1470-2045(11)70232-7  0.489
2011 Sattler M, Reddy MM, Hasina R, Gangadhar T, Salgia R. The role of the c-Met pathway in lung cancer and the potential for targeted therapy. Therapeutic Advances in Medical Oncology. 3: 171-84. PMID 21904579 DOI: 10.1177/1758834011408636  0.523
2011 Salgia R. Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer. Cancer. 117: 3889-99. PMID 21858799 DOI: 10.1002/Cncr.25935  0.502
2011 Ramalingam SS, Davies AM, Longmate J, Edelman MJ, Lara PN, Vokes EE, Villalona-Calero M, Gitlitz B, Reckamp K, Salgia R, Wright JJ, Belani CP, Gandara DR. Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003). Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: 1741-5. PMID 21716143 DOI: 10.1097/Jto.0B013E318225924C  0.419
2011 Glubb DM, Cerri E, Giese A, Zhang W, Mirza O, Thompson EE, Chen P, Das S, Jassem J, Rzyman W, Lingen MW, Salgia R, Hirsch FR, Dziadziuszko R, Ballmer-Hofer K, et al. Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 5257-67. PMID 21712447 DOI: 10.1158/1078-0432.Ccr-11-0379  0.356
2011 Zhao J, He D, Berdyshev E, Zhong M, Salgia R, Morris AJ, Smyth SS, Natarajan V, Zhao Y. Autotaxin induces lung epithelial cell migration through lysoPLD activity-dependent and -independent pathways. The Biochemical Journal. 439: 45-55. PMID 21696367 DOI: 10.1042/Bj20110274  0.425
2011 Shumway D, Corbin K, Salgia R, Hoffman P, Villaflor V, Malik RM, Haraf DJ, Vigneswaren WT, Shaikh AY, Connell PP, Ferguson MK, Salama JK. Pathologic response rates following definitive dose image-guided chemoradiotherapy and resection for locally advanced non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 74: 446-50. PMID 21676484 DOI: 10.1016/J.Lungcan.2011.05.003  0.442
2011 Ou SH, Kwak EL, Siwak-Tapp C, Dy J, Bergethon K, Clark JW, Camidge DR, Solomon BJ, Maki RG, Bang YJ, Kim DW, Christensen J, Tan W, Wilner KD, Salgia R, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: 942-6. PMID 21623265 DOI: 10.1097/Jto.0B013E31821528D3  0.52
2011 Lo FY, Tan YH, Cheng HC, Salgia R, Wang YC. An E3 ubiquitin ligase: c-Cbl: a new therapeutic target of lung cancer. Cancer. 117: 5344-50. PMID 21607942 DOI: 10.1002/Cncr.26153  0.459
2011 Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, ... ... Salgia R, et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2660-6. PMID 21606412 DOI: 10.1200/Jco.2010.32.4145  0.416
2011 Surati M, Robinson M, Nandi S, Faoro L, Demchuk C, Rolle CE, Kanteti R, Ferguson BD, Hasina R, Gangadhar TC, Salama AK, Arif Q, Kirchner C, Mendonca E, Campbell N, ... ... Salgia R, et al. Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database. Journal of Clinical Bioinformatics. 1: 1-11. PMID 21603121 DOI: 10.1186/2043-9113-1-8  0.789
2011 Tan EH, Goss GD, Salgia R, Besse B, Gandara DR, Hanna NH, Yang JC, Thertulien R, Wertheim M, Mazieres J, Hensing T, Lee C, Gupta N, Pradhan R, Qian J, et al. Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: 1418-25. PMID 21597387 DOI: 10.1097/Jto.0B013E318220C93E  0.42
2011 Catenacci DV, Cervantes G, Yala S, Nelson EA, El-Hashani E, Kanteti R, El Dinali M, Hasina R, Brägelmann J, Seiwert T, Sanicola M, Henderson L, Grushko TA, Olopade O, Karrison T, ... ... Salgia R, et al. RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biology & Therapy. 12: 9-46. PMID 21543897 DOI: 10.4161/Cbt.12.1.15747  0.453
2011 Salgia R, Hensing T, Campbell N, Salama AK, Maitland M, Hoffman P, Villaflor V, Vokes EE. Personalized treatment of lung cancer. Seminars in Oncology. 38: 274-83. PMID 21421117 DOI: 10.1053/J.Seminoncol.2011.01.012  0.462
2011 Loganathan S, Kanteti R, Siddiqui SS, El-Hashani E, Tretiakova M, Vigneswaran H, Cervantes G, Natarajan V, Husain AN, Vokes EE, Kindler HL, Salgia R. Role of protein kinase C β and vascular endothelial growth factor receptor in malignant pleural mesothelioma: Therapeutic implications and the usefulness of Caenorhabditis elegans model organism. Journal of Carcinogenesis. 10: 4. PMID 21383961 DOI: 10.4103/1477-3163.77274  0.621
2011 Jensen AR, David SY, Liao C, Dai J, Keller ET, Al-Ahmadie H, Dakin-Haché K, Usatyuk P, Sievert MF, Paner GP, Yala S, Cervantes GM, Natarajan V, Salgia R, Posadas EM. Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 3112-22. PMID 21364031 DOI: 10.1158/1078-0432.Ccr-10-1264  0.376
2011 Mollberg N, Surati M, Demchuk C, Fathi R, Salama AK, Husain AN, Hensing T, Salgia R. Mind-mapping for lung cancer: towards a personalized therapeutics approach. Advances in Therapy. 28: 173-94. PMID 21337123 DOI: 10.1007/S12325-010-0103-9  0.458
2011 Surati M, Robinson M, Nandi S, Faoro L, Demchuk C, Kanteti R, Ferguson B, Gangadhar T, Hensing T, Hasina R, Husain A, Ferguson M, Karrison T, Salgia R. Generation of comprehensive thoracic oncology database--tool for translational research. Journal of Visualized Experiments : Jove. PMID 21304468 DOI: 10.3791/2414  0.751
2011 Liu W, He L, Ramírez J, Krishnaswamy S, Kanteti R, Wang YC, Salgia R, Ratain MJ. Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletions. Cancer Research. 71: 2423-7. PMID 21292812 DOI: 10.1158/0008-5472.Can-10-2689  0.449
2011 Edelman MJ, Otterson G, Leach J, Malpass T, Salgia R, Jones D, Mody TD, Govindan R. Multicenter phase II trial of Motexafin gadolinium and pemetrexed for second-line treatment in patients with non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: 786-9. PMID 21289521 DOI: 10.1097/Jto.0B013E31820A443F  0.455
2011 Mathew B, Lennon FE, Siegler J, Mirzapoiazova T, Mambetsariev N, Sammani S, Gerhold LM, LaRiviere PJ, Chen CT, Garcia JG, Salgia R, Moss J, Singleton PA. The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. Anesthesia and Analgesia. 112: 558-67. PMID 21156980 DOI: 10.1213/Ane.0B013E31820568Af  0.476
2011 Reddy MM, Fernandes MS, Salgia R, Levine RL, Griffin JD, Sattler M. NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases. Leukemia. 25: 281-9. PMID 21072051 DOI: 10.1038/Leu.2010.263  0.344
2011 Mackinnon AC, Tretiakova M, Henderson L, Mehta RG, Yan BC, Joseph L, Krausz T, Husain AN, Reid ME, Salgia R. Paxillin expression and amplification in early lung lesions of high-risk patients, lung adenocarcinoma and metastatic disease. Journal of Clinical Pathology. 64: 16-24. PMID 21045234 DOI: 10.1136/Jcp.2010.075853  0.491
2011 Tan YC, Krishnaswamy S, Nandi S, Kanteti R, Vora S, Onel K, Hasina R, Lo F, El-Hashani E, Cervantes G, Robinson M, Hsu H, Kales SC, Lipkowitz S, Karrison T, ... ... Salgia R, et al. Correction: CBL Is Frequently Altered in Lung Cancers: Its Relationship to Mutations in MET and EGFR Tyrosine Kinases Plos One. 6. DOI: 10.1371/annotation/940edb14-522e-4f38-b6c4-7557e9a13d15  0.357
2011 Catenacci DVT, Henderson L, Cervantes G, El-Hashani E, Karrison T, Grushko T, Olopade F, Tretiakova M, Kindler HL, Salgia R. Abstract LB-124: RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma Cellular and Molecular Biology. 71. DOI: 10.1158/1538-7445.Am2011-Lb-124  0.311
2011 Glubb DM, Cerri E, Giese A, Zhang W, Mirza O, Thompson E, Jassem J, Rzyman W, Chen P, Das S, Lingen M, Salgia R, Hirsch FR, Dziadziuszko R, Ballmer-Hofer K, et al. Abstract 5136: Discovery of novel functional germline variations in the vascular endothelial growth factor receptor 2 gene (KDR) and their effect on gene expression and microvessel density in lung cancer Cancer Research. 71: 5136-5136. DOI: 10.1158/1538-7445.Am2011-5136  0.445
2011 Moss RA, Bothos JG, Patel PH, Peterson AC, Eppler S, Bai S, Nijem I, Desnoyers L, Kaur S, Zha J, Yu W, Simpson J, Ratain MJ, Tan AR, Stein MN, ... ... Salgia R, et al. Abstract 4717: Final results from the Phase I study of MetMAb, a monovalent antagonist antibody to the receptor Met, dosed as single agent and in combination with bevacizumab in patients with advanced solid malignancies Cancer Research. 71: 4717-4717. DOI: 10.1158/1538-7445.Am2011-4717  0.395
2011 Hasina R, Kawada I, Lennon F, Kanade G, Nallasura V, Kanteti R, Husain AN, Vigneswaran W, Kindler H, Vokes EE, Singleton P, Salgia R. Abstract 2341: Functional analysis of paxillin mutations identified in lung cancer and malignant mesothelioma: Implications for cell migration/motility Cancer Research. 71: 2341-2341. DOI: 10.1158/1538-7445.Am2011-2341  0.488
2011 Hasina R, Kanade G, Yala S, Mollberg N, Muller J, Surati M, Kanteti R, Husain A, Posner M, Waxman I, Vigneswaran W, Ferguson M, Villaflor V, Vokes EE, Gill P, ... Salgia R, et al. Abstract 1625: Role of EphB4 in esophageal cancer: Expression, amplification, and therapeutic inhibition Cancer Research. 71: 1625-1625. DOI: 10.1158/1538-7445.Am2011-1625  0.461
2011 Catenacci D, Henderson L, Tretiakova M, Karrison T, Salgia R. 6609 POSTER RON (MST1R) is a Novel Therapeutic Target for Gastroesophageal Adenocarcinoma European Journal of Cancer. 47: S474. DOI: 10.1016/S0959-8049(11)71920-7  0.317
2011 Solomon B, Chiappori A, Lamb A, Gawlicki M, Kim D, Park K, Salgia R, Wilner K, Reisman A, Petersen J. 3030 POSTER Preliminary Characterization of Visual Events Reported by Patients (Pts) Receiving Crizotinib for the Treatment of Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) European Journal of Cancer. 47: S231. DOI: 10.1016/S0959-8049(11)71103-0  0.463
2010 Bang Y, Kwak EL, Shaw AT, Camidge DR, Iafrate AJ, Maki RG, Solomon BJ, Ou SI, Salgia R, Clark JW. Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 3. PMID 27937460 DOI: 10.1200/Jco.2010.28.18_Suppl.3  0.473
2010 Ou SH, Bazhenova L, Camidge DR, Solomon BJ, Herman J, Kain T, Bang YJ, Kwak EL, Shaw AT, Salgia R, Maki RG, Clark JW, Wilner KD, Iafrate AJ. Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 5: 2044-6. PMID 21102269 DOI: 10.1097/Jto.0B013E318200F9Ff  0.471
2010 Song J, Li M, Tretiakova M, Salgia R, Cagle PT, Husain AN. Expression patterns of PAX5, c-Met, and paxillin in neuroendocrine tumors of the lung. Archives of Pathology & Laboratory Medicine. 134: 1702-5. PMID 21043826 DOI: 10.1043/2009-0664-Oar1.1  0.45
2010 Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, ... ... Salgia R, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. The New England Journal of Medicine. 363: 1693-703. PMID 20979469 DOI: 10.1056/Nejmoa1006448  0.51
2010 Fernandes MS, Reddy MM, Croteau NJ, Walz C, Weisbach H, Podar K, Band H, Carroll M, Reiter A, Larson RA, Salgia R, Griffin JD, Sattler M. Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism. The Journal of Biological Chemistry. 285: 32596-605. PMID 20622007 DOI: 10.1074/Jbc.M110.106161  0.358
2010 Ettinger DS, Jotte R, Lorigan P, Gupta V, Garbo L, Alemany C, Conkling P, Spigel DR, Dudek AZ, Shah C, Salgia R, McNally R, Renschler MF, Oliver JW. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 2598-603. PMID 20385980 DOI: 10.1200/Jco.2009.26.7682  0.449
2010 Faoro L, Singleton PA, Cervantes GM, Lennon FE, Choong NW, Kanteti R, Ferguson BD, Husain AN, Tretiakova MS, Ramnath N, Vokes EE, Salgia R. EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation. The Journal of Biological Chemistry. 285: 18575-85. PMID 20360610 DOI: 10.1074/Jbc.M109.075085  0.809
2010 Singleton PA, Mambetsariev N, Lennon FE, Mathew B, Siegler JH, Moreno-Vinasco L, Salgia R, Moss J, Garcia JG. Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors. Journal of Angiogenesis Research. 2: 5. PMID 20298531 DOI: 10.1186/2040-2384-2-5  0.379
2010 Saito YD, Jensen AR, Salgia R, Posadas EM. Fyn: a novel molecular target in cancer. Cancer. 116: 1629-37. PMID 20151426 DOI: 10.1002/Cncr.24879  0.419
2010 Gangadhar T, Nandi S, Salgia R. The role of chemokine receptor CXCR4 in lung cancer. Cancer Biology & Therapy. 9: 409-16. PMID 20147779 DOI: 10.4161/Cbt.9.6.11233  0.512
2010 Lawrence RE, Salgia R. MET molecular mechanisms and therapies in lung cancer. Cell Adhesion & Migration. 4: 146-52. PMID 20139696 DOI: 10.4161/Cam.4.1.10973  0.528
2010 Tan YH, Krishnaswamy S, Nandi S, Kanteti R, Vora S, Onel K, Hasina R, Lo FY, El-Hashani E, Cervantes G, Robinson M, Hsu HS, Kales SC, Lipkowitz S, Karrison T, ... ... Salgia R, et al. CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases. Plos One. 5: e8972. PMID 20126411 DOI: 10.1371/Journal.Pone.0008972  0.495
2010 Mascarenhas JB, Littlejohn EL, Wolsky RJ, Young KP, Nelson M, Salgia R, Lang D. PAX3 and SOX10 activate MET receptor expression in melanoma. Pigment Cell & Melanoma Research. 23: 225-37. PMID 20067553 DOI: 10.1111/J.1755-148X.2010.00667.X  0.386
2010 Faoro L, Cervantes GM, El-Hashani E, Salgia R. MET receptor tyrosine kinase. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 4: S1064-5. PMID 19861919 DOI: 10.1097/01.Jto.0000361752.86918.09  0.534
2010 Shah A, Singh H, Sachdev V, Lee J, Yotsukura S, Salgia R, Bharti A. Differential serum level of specific haptoglobin isoforms in small cell lung cancer Current Proteomics. 7: 49-56. DOI: 10.2174/157016410790979635  0.361
2010 Mathew B, Lennon FE, Siegler J, Gerhold L, Mambetsariev N, Moreno-Vinasco L, Garcia JG, Salgia R, Moss J, Singleton PA. Effect of methylnaltrexone inhibition of the mu opioid receptor on Lewis lung carcinoma proliferation, invasion, and angiogenesis. Journal of Clinical Oncology. 28: e13597-e13597. DOI: 10.1200/Jco.2010.28.15_Suppl.E13597  0.431
2010 Chiappori A, Schreeder MT, Moezi MM, Stephenson J, Blakely L, Salgia R, Chu QS, Ross HJ, Subramaniam DS, Berger MS. Optimizing obatoclax administration schedule: Safety and efficacy of 3-hour versus 24-hour infusion in combination with carboplatin and etoposide for patients with extensive-stage small cell lung cancer (ES-SCLC). Journal of Clinical Oncology. 28: e13531-e13531. DOI: 10.1200/Jco.2010.28.15_Suppl.E13531  0.399
2010 Soo RA, Goss GD, Salgia R, Besse B, Gandara DR, Hanna NH, Ricker JL, Qian J, Carlson DM, Tan E. Linifanib treatment in patients with non-small cell lung cancer (NSCLC): Phase II results. Journal of Clinical Oncology. 28: 7590-7590. DOI: 10.1200/Jco.2010.28.15_Suppl.7590  0.483
2010 Kurzrock R, Cohen EE, Sherman SI, Pfister DG, Cohen RB, Ball D, Hong DS, Ng CS, Salgia R, Ratain MJ. Long-term results in a cohort of medullary thyroid cancer (MTC) patients (pts) in a phase I study of XL184 (BMS 907351), an oral inhibitor of MET, VEGFR2, and RET. Journal of Clinical Oncology. 28: 5502-5502. DOI: 10.1200/Jco.2010.28.15_Suppl.5502  0.351
2010 Tan W, Wilner KD, Bang Y, Kwak EL, Maki RG, Camidge DR, Solomon BJ, Ou SI, Salgia R, Clark JW. Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients. Journal of Clinical Oncology. 28: 2596-2596. DOI: 10.1200/Jco.2010.28.15_Suppl.2596  0.39
2010 Salama AK, Pang H, Kratzke RA, Richards WG, Vokes EE, Salgia R. Interim analysis of CALGB 150607: A pilot project to study the expression of MET and P53 in resected lung adenocarcinoma specimens. Journal of Clinical Oncology. 28: 10633-10633. DOI: 10.1200/Jco.2010.28.15_Suppl.10633  0.504
2010 Salgia R, Peterson AC, Bothos J, Eppler S, Yu W, Hegde P, Yauch B, Zha J, Ratain MJ, Geary D, Wesolowsky E, LaRosiliere M, Patel P, Moss R. Abstract 2774: Complete results from a phase Ia dose-escalation and dose-expansion study of single-agent MetMAb, a monovalent antagonist antibody to the receptor MET, administered intravenously in patients with locally advanced or metastatic solid tumors Cancer Research. 70: 2774-2774. DOI: 10.1158/1538-7445.Am10-2774  0.354
2010 Cerri E, Kashyap S, Chen PX, Das S, Cipriani N, Kanteti R, Husain A, Salgia R, Innocenti F. Abstract 2176: Vascular endothelial growth factor receptor-2 (VEGFR-2) gene variations in bronchioloalveolar cell carcinoma (BAC) Cancer Research. 70: 2176-2176. DOI: 10.1158/1538-7445.Am10-2176  0.359
2010 Solomon B, Bang Y, Camidge D, Iafrate A, Kwak E, Maki R, Ou S, Salgia R, Shaw A, Clark J. 369 Timing of responses to crizotinib (PF-02341066) in anaplastic lymphoma kinase (ALK)-positive patients with advanced non-small cell lung cancer (NSCLC) European Journal of Cancer Supplements. 8: 117. DOI: 10.1016/S1359-6349(10)72076-0  0.503
2010 Shen W, Dinali ME, Braegelmann J, Zoergiebel J, Kundu A, El-Hashani E, Salgia R, Seiwert T. 198 Assessing the role of phosphoinositide 3-kinase (PI3K) in head and neck cancers European Journal of Cancer Supplements. 8: 66. DOI: 10.1016/S1359-6349(10)71903-0  0.36
2010 Pytynia M, Herman L, Chaudhary A, Darga T, Salgia R, Salama J, Chmura S. MGMT Promoter Methylation effects on Esophageal Cancer when treated with Radiation Therapy and Temozolomide International Journal of Radiation Oncology*Biology*Physics. 78: S633. DOI: 10.1016/J.Ijrobp.2010.07.1475  0.309
2009 Tan E, Salgia R, Besse B, Goss G, Gandara DR, Hanna N, Steinberg J, Steinberg J, Qian J, Carlson DM, Soo R. ABT-869 in non-small cell lung cancer (NSCLC): Interim results. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 8074. PMID 27962648 DOI: 10.1200/Jco.2009.27.15_Suppl.8074  0.448
2009 Villaflor VM, Kanteti R, Watson SM, Karrison T, Vokes EE, Salgia R. Response and survival in African American (AA) patients (pts) with non-small cell lung cancer (NSCLC) treated with erlotinib (E). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e19006. PMID 27962520 DOI: 10.1200/Jco.2009.27.15_Suppl.E19006  0.415
2009 Chiappori A, Schreeder MT, Moezi MM, Stephenson J, Blakely JL, Salgia R, Chu QS, Malik SM, Modiano MM, Berger MS. A phase Ib trial of Bcl-2 inhibitor obatoclax in combination with carboplatin and etoposide for previously untreated patients with extensive-stage small cell lung cancer (ES-SCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3576. PMID 27961715 DOI: 10.1200/Jco.2009.27.15_Suppl.3576  0.439
2009 Faoro L, Cervantes GM, Ferguson BD, Seiwert TY, Yala S, Vigneswaran WT, Westerhoff M, Tretiakova MS, Ferguson MK, Moura GL, Husain AN, Vokes EE, Salgia R. MET/PKCbeta expression correlate with metastasis and inhibition is synergistic in lung cancer. Journal of Carcinogenesis. 8: 15. PMID 19955662 DOI: 10.4103/1477-3163.57857  0.817
2009 Ray M, Salgia R, Vokes EE. The role of EGFR inhibition in the treatment of non-small cell lung cancer. The Oncologist. 14: 1116-30. PMID 19892771 DOI: 10.1634/Theoncologist.2009-0054  0.466
2009 Kanteti R, Yala S, Ferguson MK, Salgia R. MET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance. Journal of Environmental Pathology, Toxicology and Oncology : Official Organ of the International Society For Environmental Toxicology and Cancer. 28: 89-98. PMID 19817696 DOI: 10.1615/Jenvironpatholtoxicoloncol.V28.I2.10  0.365
2009 Yang J, Price MA, Li GY, Bar-Eli M, Salgia R, Jagedeeswaran R, Carlson JH, Ferrone S, Turley EA, McCarthy JB. Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition. Cancer Research. 69: 7538-47. PMID 19738072 DOI: 10.1158/0008-5472.Can-08-4626  0.353
2009 Krishnaswamy S, Kanteti R, Duke-Cohan JS, Loganathan S, Liu W, Ma PC, Sattler M, Singleton PA, Ramnath N, Innocenti F, Nicolae DL, Ouyang Z, Liang J, Minna J, Kozloff MF, ... ... Salgia R, et al. Ethnic differences and functional analysis of MET mutations in lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 5714-23. PMID 19723643 DOI: 10.1158/1078-0432.Ccr-09-0070  0.413
2009 Mascarenhas JB, Young KP, Littlejohn EL, Yoo BK, Salgia R, Lang D. PAX6 is expressed in pancreatic cancer and actively participates in cancer progression through activation of the MET tyrosine kinase receptor gene. The Journal of Biological Chemistry. 284: 27524-32. PMID 19651775 DOI: 10.1074/Jbc.M109.047209  0.409
2009 Salgia R. Role of c-Met in cancer: emphasis on lung cancer. Seminars in Oncology. 36: S52-8. PMID 19393836 DOI: 10.1053/J.Seminoncol.2009.02.008  0.488
2009 Kim ES, Salgia R. MET pathway as a therapeutic target. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 4: 444-7. PMID 19333071 DOI: 10.1097/Jto.0B013E31819D6F91  0.361
2009 Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, Yala S, Kanteti R, Cohen EE, Lingen MW, Martin L, Krishnaswamy S, Klein-Szanto A, Christensen JG, Vokes EE, ... Salgia R, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Research. 69: 3021-31. PMID 19318576 DOI: 10.1158/0008-5472.Can-08-2881  0.463
2009 Kanteti R, Nallasura V, Loganathan S, Tretiakova M, Kroll T, Krishnaswamy S, Faoro L, Cagle P, Husain AN, Vokes EE, Lang D, Salgia R. PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription. Laboratory Investigation; a Journal of Technical Methods and Pathology. 89: 301-14. PMID 19139719 DOI: 10.1038/Labinvest.2008.168  0.437
2009 Tang Z, Jiang S, Du R, Petri ET, El-Telbany A, Chan PS, Kijima T, Dietrich S, Matsui K, Kobayashi M, Sasada S, Okamoto N, Suzuki H, Kawahara K, Iwasaki T, ... ... Salgia R, et al. Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity. Oncogene. 28: 518-33. PMID 19015641 DOI: 10.1038/Onc.2008.411  0.435
2009 Posadas EM, Al-Ahmadie H, Robinson VL, Jagadeeswaran R, Otto K, Kasza KE, Tretiakov M, Siddiqui J, Pienta KJ, Stadler WM, Rinker-Schaeffer C, Salgia R. FYN is overexpressed in human prostate cancer. Bju International. 103: 171-7. PMID 18990162 DOI: 10.1111/J.1464-410X.2008.08009.X  0.329
2009 Kwak E, Camidge D, Clark J, Shapiro G, Maki R, Ratain M, Solomon B, Bang Y, Ou S, Salgia R. G6 Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066 European Journal of Cancer Supplements. 7: 8. DOI: 10.1200/Jco.2009.27.15_Suppl.3509  0.337
2009 Reddy MM, Fernandes M, Salgia R, Levine RL, Griffin JD, Sattler M. NADPH Oxidases Are Important Regulators of Growth and Migration in Myeloid Neoplasms. Blood. 114: 2190-2190. DOI: 10.1182/Blood.V114.22.2190.2190  0.356
2009 Lennon FE, Mambetsariev N, Garcia JGN, Salgia R, Moss J, Singleton PA. Abstract C79: Methylnaltrexone inhibits EGF‐ and IGF‐induced human bronchioloalveolar carcinoma proliferation and migration Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-C79  0.478
2009 Mathew B, Lennon FE, Siegler J, Gerhold L, Mambetsariev N, Moreno‐Vinasco L, Garcia JGN, Salgia R, Moss J, Singleton P. Abstract C78: The mu opioid receptor regulates Lewis lung carcinoma tumor growth and metastasis Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-C78  0.424
2009 Dinali ME, Braegelmann J, Stricker T, Brown C, Salgia R, Vokes E, White K, Seiwert T. Abstract A207: Whole transcriptome profiling in upper aerodigestive tract cancers Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-A207  0.35
2009 Zoergiebel J, Kundu A, Braegelmann J, Shen W, Dinali ME, Salgia R, Seiwert T. Abstract A165: Determining drug inhibition profiles and opportunities for synergistic combination therapies in head and neck cancer cell lines Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-A165  0.38
2009 Ettinger D, Jotte R, Lorigan P, Gupta V, Garbo L, Spigel D, Dudek A, Salgia R, McNally R, Renschler M. 9121 Amrubicin monotherapy in patients with extensive disease small cell lung cancer (ED-SCLC) refractory to first-line platinum-based chemotherapy: final results of a phase 2 trial European Journal of Cancer Supplements. 7: 541. DOI: 10.1016/S1359-6349(09)71834-8  0.459
2009 Tan E, Goss G, Salgia R, Besse B, Gandara D, Hanna N, Ricker J, Qian J, Carlson D, Soo R. 9013 Phase II results of ABT-869 treatment in patients with non small cell lung cancer (NSCLC) European Journal of Cancer Supplements. 7: 509-510. DOI: 10.1016/S1359-6349(09)71726-4  0.37
2008 Salgia R, Sherman S, Hong DS, Ng CS, Frye J, Janisch L, Ratain MJ, Kurzrock R. A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 3522. PMID 27949731 DOI: 10.1200/Jco.2008.26.15_Suppl.3522  0.425
2008 Rizvi NA, Kris MG, Miller VA, Krug LM, Bekele S, Dowlati A, Rowland KM, Salgia R, Aggarwal N, Gadgeel SM. Activity of XL647 in clinically selected NSCLC patients (pts) enriched for the presence of EGFR mutations: Results from Phase 2. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 8053. PMID 27948945 DOI: 10.1200/Jco.2008.26.15_Suppl.8053  0.401
2008 Faoro L, Hutto JY, Salgia R, El-Zayaty SA, Ferguson MK, Cheney RT, Reid ME, Armato SG, Krausz T, Husain AN. Lymphatic vessel density is not associated with lymph node metastasis in non-small cell lung carcinoma. Archives of Pathology & Laboratory Medicine. 132: 1882-8. PMID 19061284 DOI: 10.1043/1543-2165-132.12.1882  0.352
2008 Sattler M, Abidoye O, Salgia R. EGFR-targeted therapeutics: focus on SCCHN and NSCLC. Thescientificworldjournal. 8: 909-19. PMID 18836658 DOI: 10.1100/Tsw.2008.117  0.485
2008 Faoro L, Loganathan S, Westerhoff M, Modi R, Husain AN, Tretiakova M, Seiwert T, Kindler HL, Vokes EE, Salgia R. Protein kinase C beta in malignant pleural mesothelioma. Anti-Cancer Drugs. 19: 841-8. PMID 18765998 DOI: 10.1097/Cad.0B013E32830Ce506  0.383
2008 Choong NW, Mauer AM, Haraf DJ, Lester E, Hoffman PC, Kozloff M, Lin S, Dancey JE, Szeto L, Grushko T, Olopade OI, Salgia R, Vokes EE. Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 3: 1003-11. PMID 18758303 DOI: 10.1097/Jto.0B013E31818396A4  0.387
2008 Ma PC, Tretiakova MS, MacKinnon AC, Ramnath N, Johnson C, Dietrich S, Seiwert T, Christensen JG, Jagadeeswaran R, Krausz T, Vokes EE, Husain AN, Salgia R. Expression and mutational analysis of MET in human solid cancers. Genes, Chromosomes & Cancer. 47: 1025-37. PMID 18709663 DOI: 10.1002/Gcc.20604  0.481
2008 Cipriani NA, Abidoye OO, Vokes E, Salgia R. MET as a target for treatment of chest tumors. Lung Cancer (Amsterdam, Netherlands). 63: 169-79. PMID 18672314 DOI: 10.1016/J.Lungcan.2008.06.011  0.527
2008 Sittler T, Zhou J, Park J, Yuen NK, Sarantopoulos S, Mollick J, Salgia R, Giobbie-Hurder A, Dranoff G, Hodi FS. Concerted potent humoral immune responses to autoantigens are associated with tumor destruction and favorable clinical outcomes without autoimmunity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 3896-905. PMID 18559611 DOI: 10.1158/1078-0432.Ccr-07-4782  0.31
2008 Jackman DM, Kindler HL, Yeap BY, Fidias P, Salgia R, Lucca J, Morse LK, Ostler PA, Johnson BE, Jänne PA. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer. 113: 808-14. PMID 18543326 DOI: 10.1002/Cncr.23617  0.392
2008 Menezes RJ, Cheney RT, Husain A, Tretiakova M, Loewen G, Johnson CS, Jayaprakash V, Moysich KB, Salgia R, Reid ME. Vitamin D receptor expression in normal, premalignant, and malignant human lung tissue. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 17: 1104-10. PMID 18483332 DOI: 10.1158/1055-9965.Epi-07-2713  0.426
2008 Abidoye O, Murukurthy N, Salgia R. Review of clinic trials: agents targeting c-Met. Reviews On Recent Clinical Trials. 2: 143-7. PMID 18473999 DOI: 10.2174/157488707780599357  0.435
2008 Nimeiri HS, Oza AM, Morgan RJ, Friberg G, Kasza K, Faoro L, Salgia R, Stadler WM, Vokes EE, Fleming GF. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecologic Oncology. 110: 49-55. PMID 18423560 DOI: 10.1016/J.Ygyno.2008.02.009  0.33
2008 Siddiqui SS, Loganathan S, Krishnaswamy S, Faoro L, Jagadeeswaran R, Salgia R. C. elegans as a model organism for in vivo screening in cancer: effects of human c-Met in lung cancer affect C. elegans vulva phenotypes. Cancer Biology & Therapy. 7: 856-63. PMID 18340114 DOI: 10.4161/Cbt.7.6.5842  0.661
2008 Rudin CM, Salgia R, Wang X, Hodgson LD, Masters GA, Green M, Vokes EE. Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 870-6. PMID 18281659 DOI: 10.1200/Jco.2007.14.3461  0.386
2008 Jagadeeswaran R, Surawska H, Krishnaswamy S, Janamanchi V, Mackinnon AC, Seiwert TY, Loganathan S, Kanteti R, Reichman T, Nallasura V, Schwartz S, Faoro L, Wang YC, Girard L, Tretiakova MS, ... ... Salgia R, et al. Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Research. 68: 132-42. PMID 18172305 DOI: 10.1158/0008-5472.Can-07-1998  0.501
2008 Koon EC, Ma PC, Salgia R, Welch WR, Christensen JG, Berkowitz RS, Mok SC. Effect of a c-Met-specific, ATP-competitive small-molecule inhibitor SU11274 on human ovarian carcinoma cell growth, motility, and invasion. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 18: 976-84. PMID 18021219 DOI: 10.1111/J.1525-1438.2007.01135.X  0.381
2008 Gordon GJ, Mani M, Maulik G, Mukhopadhyay L, Yeap BY, Kindler HL, Salgia R, Sugarbaker DJ, Bueno R. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemotherapy and Pharmacology. 61: 549-58. PMID 17522864 DOI: 10.1007/S00280-007-0500-1  0.384
2008 Maitland ML, Kasza KE, Lacouture ME, Liu W, Soltani K, Kozloff MF, Hoffman PC, Salgia R, Karrison T, Vokes EE. Refining epidermal growth factor receptor (EGFR) -inhibition-related rash (EIRR) phenotypes with a cetuximab (C) monotherapy stage of a phase II trial for non-small cell lung cancer (NSCLC) Journal of Clinical Oncology. 26: 8089-8089. DOI: 10.1200/Jco.2008.26.15_Suppl.8089  0.412
2008 Faoro L, Cohen EE, Govindan R, Kozloff MF, Hoffman PC, Maitland ML, Verel K, Szeto L, Salgia R, Vokes EE. Phase II trial of sequential bevacizumab (B), erlotinib (E) and chemotherapy for first line treatment of clinical stage IIIB or IV non-small cell lung cancer (NSCLC) Journal of Clinical Oncology. 26: 19130-19130. DOI: 10.1200/Jco.2008.26.15_Suppl.19130  0.345
2008 Salgia R, Peterson A, Eppler S, Yu W, Polite B, Geary D, Wesolowski E, LaRosiliere M, Ratain M, Sovak M. 411 POSTER A phase I, open-label, dose-escalation study of the safety and pharmacology of MetMAb, a monovalent antagonist antibody to the receptor c-Met, administered IV in patients with locally advanced or metastatic solid tumors European Journal of Cancer Supplements. 6: 129. DOI: 10.1016/S1359-6349(08)72345-0  0.303
2008 Kurzrock R, Sherman S, Hong D, Ng C, Frye J, Janisch L, Ratain M, Salgia R. 379 POSTER A phase I study of XL184, a MET, VEGFR2, and RET kinase inhibitor, administered orally to patients (pts) with advanced malignancies, including a subgroup of pts with medullary thyroid cancer (MTC) European Journal of Cancer Supplements. 6: 119. DOI: 10.1016/S1359-6349(08)72313-9  0.377
2007 Hahn O, Salgia R. Non-receptor tyrosine kinase inhibitors in lung cancer. Anti-Cancer Agents in Medicinal Chemistry. 7: 633-42. PMID 18045058 DOI: 10.2174/187152007784111322  0.522
2007 Singleton PA, Salgia R, Moreno-Vinasco L, Moitra J, Sammani S, Mirzapoiazova T, Garcia JG. CD44 regulates hepatocyte growth factor-mediated vascular integrity. Role of c-Met, Tiam1/Rac1, dynamin 2, and cortactin. The Journal of Biological Chemistry. 282: 30643-57. PMID 17702746 DOI: 10.1074/Jbc.M702573200  0.314
2007 Zhao Y, He D, Stern R, Usatyuk PV, Spannhake EW, Salgia R, Natarajan V. Lysophosphatidic acid modulates c-Met redistribution and hepatocyte growth factor/c-Met signaling in human bronchial epithelial cells through PKC delta and E-cadherin. Cellular Signalling. 19: 2329-38. PMID 17689924 DOI: 10.1016/J.Cellsig.2007.07.005  0.321
2007 Ma PC, Tretiakova MS, Nallasura V, Jagadeeswaran R, Husain AN, Salgia R. Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion. British Journal of Cancer. 97: 368-77. PMID 17667909 DOI: 10.1038/Sj.Bjc.6603884  0.385
2007 Shaikh AY, Haraf DJ, Salama JK, Salgia R, Hoffman PC, Ferguson MK, Connell PP. Chemotherapy and high dose radiotherapy followed by resection for locally advanced nonsmall cell lung cancers. American Journal of Clinical Oncology. 30: 258-63. PMID 17551302 DOI: 10.1097/01.Coc.0000258109.83083.78  0.46
2007 Puri N, Khramtsov A, Ahmed S, Nallasura V, Hetzel JT, Jagadeeswaran R, Karczmar G, Salgia R. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Research. 67: 3529-34. PMID 17440059 DOI: 10.1158/0008-5472.Can-06-4416  0.522
2007 Bharti A, Ma PC, Salgia R. Biomarker discovery in lung cancer--promises and challenges of clinical proteomics. Mass Spectrometry Reviews. 26: 451-66. PMID 17407130 DOI: 10.1002/Mas.20125  0.468
2007 Puri N, Ahmed S, Janamanchi V, Tretiakova M, Zumba O, Krausz T, Jagadeeswaran R, Salgia R. c-Met is a potentially new therapeutic target for treatment of human melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 2246-53. PMID 17404109 DOI: 10.1158/1078-0432.Ccr-06-0776  0.374
2007 Choong NW, Salgia R, Vokes EE. Key signaling pathways and targets in lung cancer therapy. Clinical Lung Cancer. S52-60. PMID 17382025 DOI: 10.3816/Clc.2007.S.002  0.507
2007 Jagadeeswaran R, Jagadeeswaran S, Bindokas VP, Salgia R. Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells. American Journal of Physiology. Lung Cellular and Molecular Physiology. 292: L1488-94. PMID 17322284 DOI: 10.1152/Ajplung.00147.2006  0.436
2007 Lengyel E, Sawada K, Salgia R. Tyrosine kinase mutations in human cancer. Current Molecular Medicine. 7: 77-84. PMID 17311534 DOI: 10.2174/156652407779940486  0.388
2007 Sawada K, Radjabi AR, Shinomiya N, Kistner E, Kenny H, Becker AR, Turkyilmaz MA, Salgia R, Yamada SD, Vande Woude GF, Tretiakova MS, Lengyel E. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Research. 67: 1670-9. PMID 17308108 DOI: 10.1158/0008-5472.Can-06-1147  0.422
2007 Sattler M, Salgia R. c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy. Current Oncology Reports. 9: 102-8. PMID 17288874 DOI: 10.1007/S11912-007-0005-4  0.409
2007 Abidoye O, Ferguson MK, Salgia R. Lung carcinoma in African Americans. Nature Clinical Practice. Oncology. 4: 118-29. PMID 17259932 DOI: 10.1038/Ncponc0718  0.446
2007 Seiwert TY, Connell PP, Mauer AM, Hoffman PC, George CM, Szeto L, Salgia R, Posther KE, Nguyen B, Haraf DJ, Vokes EE. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 515-22. PMID 17255273 DOI: 10.1158/1078-0432.Ccr-06-1058  0.37
2007 Faoro L, Loganathan S, Husain A, Westerhoff M, Janamanchi V, Vokes E, Salgia R. Expression of protein kinase C beta (PKCß) as a prognostic marker in non-small cell lung cancer (NSCLC) and mesothelioma Journal of Clinical Oncology. 25: 7656-7656. DOI: 10.1200/Jco.2007.25.18_Suppl.7656  0.467
2007 Nimeiri HS, Faoro L, Oza AM, Morgan RJ, Gandara D, Janamanchi V, Salgia R, Stadler WM, Vokes EE, Fleming GF. Molecular correlates (EGFR status) and plasma VEGF levels associated with a phase II study of bevacizumab plus erlotinib (BE) for patients with recurrent ovarian cancer (OC) and fallopian tube (FT) cancer Journal of Clinical Oncology. 25: 5554-5554. DOI: 10.1200/Jco.2007.25.18_Suppl.5554  0.342
2007 Innocenti F, Janisch L, Das S, Ramirez J, House L, Maitland ML, Salgia R, Ratain MJ. A genotype-directed phase I study of irinotecan in advanced cancer patients Journal of Clinical Oncology. 25: 2502-2502. DOI: 10.1200/Jco.2007.25.18_Suppl.2502  0.303
2007 Villaflor VM, Faoro L, Hutto J, Varalakshmi J, Suzue K, Vokes E, Husein A, Salgia R. Lymphatic vessel density is not associated with lymph node metastasis or survival in non-small cell lung carcinoma (NSCLC) Journal of Clinical Oncology. 25: 18008-18008. DOI: 10.1200/Jco.2007.25.18_Suppl.18008  0.359
2007 Salgia R, Hong DS, Camacho LH, Ng CS, Janisch L, Ratain MJ, Kurzrock R. A phase I dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies Journal of Clinical Oncology. 25: 14031-14031. DOI: 10.1200/Jco.2007.25.18_Suppl.14031  0.343
2007 Singleton PA, Salgia R, Moreno-Vinasco L, Moitra J, Sammani S, Mirzapoiazova T, Dudek SM, Garcia J. 89 LIPID RAFT REGULATION OF HEPATOCYTE GROWTH FACTOR/C-MET-MEDIATED VASCULAR INTEGRITY: ROLE OF CD44, TIAM1/RAC1, DYNAMIN 2, AND CORTACTIN. Journal of Investigative Medicine. 55: S363.3-S363. DOI: 10.1136/Jim-55-02-89  0.312
2007 Govindan R, Cohen EE, Kozloff MF, Mauer AM, Hoffman PC, Karrison T, Schwegman J, Szeto L, Salgia R, Vokes EE. P3-087: Phase II trial of sequenced bevacizumab and erlotinib with bevacizumab and chemotherapy for 1st line stage IIIB or IV Non-small cell lung cancer (NSCLC) Journal of Thoracic Oncology. 2: S716. DOI: 10.1097/01.Jto.0000284063.57103.13  0.437
2007 Kanteti R, Nallasura V, Wang C, Hasan R, Loganathan S, Jagadeeswaran R, Husain A, Lang D, Salgia R. P2-126: The role of pax transcription factors in lung carcinogenesis: relationship to c-Met receptor tyrosine kinase Journal of Thoracic Oncology. 2: S541. DOI: 10.1097/01.Jto.0000283590.09867.63  0.39
2007 Jagadeeswaran R, Zumba O, Salgia R. P2-125: Amplification of c-Met in a subset of lung cancer cells leads to activation of m-Tor pathway Journal of Thoracic Oncology. 2: S540-S541. DOI: 10.1097/01.Jto.0000283589.02244.75  0.444
2007 Jagadeeswaran R, Zumba O, Krishnaswamy S, Janamanchi V, Seiwert TY, Loganathan S, Kanteti R, Nallasura V, Faoro L, Vokes EE, Salgia R. P2-124: Focal adhesion paxillin induces nodular cell growth, invasion, and angiogenesis in lung cancer Journal of Thoracic Oncology. 2: S540. DOI: 10.1097/01.Jto.0000283588.25114.3A  0.457
2007 Jagadeeswaran R, Salgia R. PD6-1-3: HGF/c-Met axis modulate Topoisomerase-I activity and cell viability in small cell lung cancer Journal of Thoracic Oncology. 2: S425. DOI: 10.1097/01.Jto.0000283325.91107.90  0.426
2007 Seiwert T, Rocchi P, Bracht L, Janamanchi V, Jagadeeswaran R, Husain A, Tan D, Qiang L, Gleave M, Salgia R. A5-06: Heat shock protein 27 - a novel target for non-small cell lung cancer and possible marker of metastasis Journal of Thoracic Oncology. 2: S325. DOI: 10.1097/01.Jto.0000283123.90401.9F  0.425
2007 Salgia R. E02-02: Prognostic and predictive markers in lung cancer-emphasis on receptor tyrosine kinases egfr and met Journal of Thoracic Oncology. 2: S218. DOI: 10.1097/01.Jto.0000282993.43307.94  0.453
2007 Seiwert T, Janamanchi V, Klein-Szanto A, Jagadeeswaran R, Martin L, Lingen M, Cohen E, Ridge J, Vokes E, Salgia R. The Receptor Tyrosine Kinase c-MET as a Novel Therapeutic Target in Head and Neck Cancer International Journal of Radiation Oncology*Biology*Physics. 69: S137. DOI: 10.1016/J.Ijrobp.2007.06.004  0.405
2006 Chhatriwala H, Jafri N, Salgia R. A review of topoisomerase inhibition in lung cancer. Cancer Biology & Therapy. 5: 1600-7. PMID 17224634 DOI: 10.4161/Cbt.5.12.3546  0.49
2006 Nicholas MK, Lukas RV, Jafri NF, Faoro L, Salgia R. Epidermal growth factor receptor-mediated signal transduction in the development and therapy of gliomas Clinical Cancer Research. 12: 7261-7270. PMID 17189397 DOI: 10.1158/1078-0432.Ccr-06-0874  0.385
2006 Ahmed SM, Salgia R. Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer. Respirology (Carlton, Vic.). 11: 687-92. PMID 17052295 DOI: 10.1111/J.1440-1843.2006.00887.X  0.484
2006 Maitland ML, Wilcox R, Hogarth DK, Desai AA, Caligiuri P, Abrahams C, Salgia R. Diffuse alveolar damage after a single dose of topotecan in a patient with pulmonary fibrosis and small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 54: 243-5. PMID 16949700 DOI: 10.1016/J.Lungcan.2006.07.017  0.381
2006 Choong NW, Dietrich S, Seiwert TY, Tretiakova MS, Nallasura V, Davies GC, Lipkowitz S, Husain AN, Salgia R, Ma PC. Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation. Nature Clinical Practice. Oncology. 3: 50-7; quiz 1 p follo. PMID 16407879 DOI: 10.1038/Ncponc0400  0.479
2006 Jagadeeswaran R, Ma PC, Seiwert TY, Jagadeeswaran S, Zumba O, Nallasura V, Ahmed S, Filiberti R, Paganuzzi M, Puntoni R, Kratzke RA, Gordon GJ, Sugarbaker DJ, Bueno R, Janamanchi V, ... ... Salgia R, et al. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Research. 66: 352-61. PMID 16397249 DOI: 10.1158/0008-5472.Can-04-4567  0.38
2006 Pisick E, Salgia R. Molecular biology of malignant mesothelioma: a review. Hematology/Oncology Clinics of North America. 19: 997-1023, v. PMID 16325120 DOI: 10.1016/J.Hoc.2005.09.012  0.344
2006 Choong NW, Dietrich S, Seiwert TY, Tretiakova MS, Nallasura V, Davies GC, Lipkowitz S, Husain AN, Salgia R, Ma PC. 70 GEFITINIB RESPONSE OF ERLOTINIB-REFRACTORY LUNG CANCER WITH LEPTOMENINGEAL METASTASIS. Journal of Investigative Medicine. 54: S355.2-S355. DOI: 10.2310/6650.2005.X0015.69  0.463
2006 Blumenschein G, Sandler A, O’Rourke T, Eschenberg M, Sun Y, Gladish G, Salgia R, Alden C, Herbst RS, Reckamp K. Safety and pharmacokinetics (PK) of AMG 706, panitumumab, and carboplatin/paclitaxel (CP) for the treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC) Journal of Clinical Oncology. 24: 7119-7119. DOI: 10.1200/Jco.2006.24.18_Suppl.7119  0.361
2006 Seiwert T, Bracht L, Rocchi P, Tan D, Ramnath N, Jagadeeswaran R, Varalakshmi J, Husain A, Gleave M, Salgia R. 381 POSTER HSP27 as a novel target in Non-small cell lung cancer with particular implications for migration and metastasis European Journal of Cancer Supplements. 4: 117-118. DOI: 10.1016/S1359-6349(06)70386-X  0.495
2006 Cohen E, Govindan R, Kozloff M, Mauer A, Hoffman P, Karrison T, Stein J, Szeto L, Salgia R, Vokes E. 130 POSTER Phase II trial of Sequenced Bevacizumab and Erlotinib with Bevacizumab and Chemotherapy for 1st Line Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC) European Journal of Cancer Supplements. 4: 42-43. DOI: 10.1016/S1359-6349(06)70136-7  0.439
2006 Seiwert TY, Klein-Szanto AJ, Jagadeeswaran R, Tretiakova M, Martin L, Lingen MW, Cohen EE, Ridge JA, Vokes EE, Salgia R. S115 The Receptor Tyrosine Kinase c-MET Is Mutated in Head and Neck Cancer and Is a Promising Novel Target Archives of Otolaryngology–Head & Neck Surgery. 132: 864. DOI: 10.1001/Archotol.132.8.864-B  0.373
2005 Rudin CM, Salgia R, Wang XF, Green MR, Vokes EE. CALGB 30103: A randomized phase II study of carboplatin and etoposide (CE) with or without G3139 in patients with extensive stage small cell lung cancer (ES-SCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 7168. PMID 27944986 DOI: 10.1200/Jco.2005.23.16_Suppl.7168  0.395
2005 Cunningham C, Richards D, Salgia R, Leonard R, Raju R, Arseneau J, Packer S, Gregoire L, Haltom E, Uprichard MJ. Phase 2 trial of talabostat and docetaxel in patients with stage IIIb/IV NSCLC. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 7120. PMID 27944217 DOI: 10.1200/Jco.2005.23.16_Suppl.7120  0.315
2005 Jacobs M, Weber R, Hainsworth J, Schwartzberg L, Strauss J, Tatsuta N, Du Z, McLeod M, Dahl T, Salgia R. A phase 1/2 study of STA-4783 in combination with paclitaxel and carboplatin in chemo-naïve advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 7106. PMID 27944185 DOI: 10.1200/Jco.2005.23.16_Suppl.7106  0.396
2005 Chu F, Barkinge J, Hawkins S, Gudi R, Salgia R, Kanteti PV. Expression of Siva-1 protein or its putative amphipathic helical region enhances cisplatin-induced apoptosis in breast cancer cells: effect of elevated levels of BCL-2. Cancer Research. 65: 5301-9. PMID 15958577 DOI: 10.1158/0008-5472.Can-04-3270  0.337
2005 Choong NW, Ma PC, Salgia R. Therapeutic targeting of receptor tyrosine kinases in lung cancer. Expert Opinion On Therapeutic Targets. 9: 533-59. PMID 15948672 DOI: 10.1517/14728222.9.3.533  0.513
2005 Hahn O, Salgia R. Novel therapies in lung cancer. Hematology/Oncology Clinics of North America. 19: 343-67, vii. PMID 15833410 DOI: 10.1016/J.Hoc.2005.02.005  0.49
2005 Ma PC, Schaefer E, Christensen JG, Salgia R. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 2312-9. PMID 15788682 DOI: 10.1158/1078-0432.Ccr-04-1708  0.336
2005 Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, Hansen M, Schaefer E, Naoki K, Lader A, Richards W, Sugarbaker D, Husain AN, Christensen JG, Salgia R. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Research. 65: 1479-88. PMID 15735036 DOI: 10.1158/0008-5472.Can-04-2650  0.479
2005 Seiwert TY, Connell PP, Mauer AM, Hoffman PC, George CM, Szeto L, Obasaju C, Haraf DJ, Salgia R, Vokes EE. A phase I dose-escalating study of combination pemetrexed-based chemotherapy and concomitant radiotherapy for locally advanced or metastatic non-small cell lung or esophageal cancer Journal of Clinical Oncology. 23: 7062-7062. DOI: 10.1200/Jco.2005.23.16_Suppl.7062  0.462
2005 Frizelle S, Ma P, Salgia R, Kumar P, Hoang C, Kratzke R. P-398 Matriptase is overexpressed in malignant mesothelioma and maybe blocked by matriptase inhibitors leading to decreased cell invasion Lung Cancer. 49: S220. DOI: 10.1016/S0169-5002(05)80891-8  0.323
2005 Seiwert T, Treatiakova M, Ma P, Khaleque M, Husain A, Ladanyi A, Chen L, Bharti A, Salgia R. P-112 Heat shock proteins (HSPs) as a potential novel target in lung cancer Lung Cancer. 49: S144. DOI: 10.1016/S0169-5002(05)80606-3  0.389
2005 Seiwert T, Connell P, Mauer A, Hoffman P, George C, Szeto L, Salgia R, Kayitalire L, Haraf D, Vokes E. PD-48 Pemetrexed-based concurrent chemoradiotherapy (CRT)for locally advanced or metastatic non-small cell lung or esophageal cancer: A phase I dose-escalating study Lung Cancer. 49: S80. DOI: 10.1016/S0169-5002(05)80381-2  0.425
2005 Ma P, Dietrich S, Fox E, Naoki K, Schaefer E, Lader A, Richards W, Sugarbaker D, Jagadeeswaran R, Salgia R. O-193 Novel semaphorin- and juxtamembrane-domain mutations ofc-MET in NSCLC: Potential for targeted inhibition Lung Cancer. 49: S64-S65. DOI: 10.1016/S0169-5002(05)80328-9  0.312
2005 Shaikh A, Haraf D, Salgia R, Hoffman P, Ferguson M, Connell P. Stage IIIA Non-Small Cell Lung Cancers Treated with Neoadjuvant Concurrent Chemotherapy and High Dose Radiotherapy Followed by Resection International Journal of Radiation Oncology*Biology*Physics. 63: S418-S419. DOI: 10.1016/J.Ijrobp.2005.07.711  0.446
2004 Ma PC, Tretiakova MS, Jagadeeswaran R, Jagadeesh S, Nallasura V, Kindler HL, Lingen M, Vokes EE, Husain A, Salgia R. Role of c-MET in lung cancer, malignant mesothelioma, and head and neck cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 9539. PMID 28016812 DOI: 10.1200/Jco.2004.22.14_Suppl.9539  0.475
2004 Ma PC, Salgia R. Novel targets for therapeutic agents in small cell lung cancer. Journal of the National Comprehensive Cancer Network : Jnccn. 2: 165-72. PMID 19777705 DOI: 10.6004/Jnccn.2004.0014  0.517
2004 Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Letters. 225: 1-26. PMID 15922853 DOI: 10.1016/J.Canlet.2004.09.044  0.441
2004 Surawska H, Ma PC, Salgia R. The role of ephrins and Eph receptors in cancer. Cytokine & Growth Factor Reviews. 15: 419-33. PMID 15561600 DOI: 10.1016/J.Cytogfr.2004.09.002  0.434
2004 Maulik G, Bharti A, Khan E, Broderick RJ, Kijima T, Salgia R. Modulation of c-Kit/SCF pathway leads to alterations in topoisomerase-I activity in small cell lung cancer. Journal of Environmental Pathology, Toxicology and Oncology : Official Organ of the International Society For Environmental Toxicology and Cancer. 23: 237-51. PMID 15511212 DOI: 10.1615/Jenvpathtoxoncol.V23.I4.10  0.418
2004 Pisick E, Jagadeesh S, Salgia R. Receptor tyrosine kinases and inhibitors in lung cancer. Thescientificworldjournal. 4: 589-604. PMID 15349502 DOI: 10.1100/Tsw.2004.117  0.499
2004 Mukhopadhyay NK, Gilchrist D, Gordon GJ, Chen CJ, Bueno R, Lu ML, Salgia R, Sugarbaker DJ, Jaklitsch MT. Integrin-dependent protein tyrosine phosphorylation is a key regulatory event in collagen-IV-mediated adhesion and proliferation of human lung tumor cell line, Calu-1. The Annals of Thoracic Surgery. 78: 450-7. PMID 15276495 DOI: 10.1016/J.Athoracsur.2004.01.042  0.426
2004 Sattler M, Ma PC, Salgia R. Therapeutic targeting of the receptor tyrosine kinase Met. Cancer Treatment and Research. 119: 121-38. PMID 15164876 DOI: 10.1007/1-4020-7847-1_7  0.397
2004 Bharti A, Ma PC, Maulik G, Singh R, Khan E, Skarin AT, Salgia R. Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer. Anticancer Research. 24: 1031-8. PMID 15154618  0.306
2004 Sattler M, Salgia R. Targeting c-Kit mutations: basic science to novel therapies. Leukemia Research. S11-20. PMID 15036937 DOI: 10.1016/J.Leukres.2003.10.004  0.434
2004 Murray N, Salgia R, Fossella FV. Targeted molecules in small cell lung cancer. Seminars in Oncology. 31: 106-11. PMID 14981588 DOI: 10.1053/J.Seminoncol.2003.12.021  0.525
2004 Pisick E, Jagadeesh S, Salgia R. Small cell lung cancer: from molecular biology to novel therapeutics. Journal of Experimental Therapeutics & Oncology. 3: 305-18. PMID 14678519 DOI: 10.1111/J.1533-869X.2003.01103.X  0.455
2003 Johnson BE, Fischer T, Fischer B, Dunlop D, Rischin D, Silberman S, Kowalski MO, Sayles D, Dimitrijevic S, Fletcher C, Hornick J, Salgia R, Le Chevalier T. Phase II study of imatinib in patients with small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 5880-7. PMID 14676110  0.352
2003 Salgia R, Skaring AT. p53 and Bcl-2 in small cell-lung cancer. Clinical Lung Cancer. 4: 303. PMID 14609449  0.368
2003 Lee D, Belani CP, Salgia R. Benefit of active treatment in non-small-cell lung cancer in elderly patients and patients with poor performance status. Clinical Lung Cancer. 5: 86-89. PMID 14596690 DOI: 10.1016/S1525-7304(11)70325-4  0.467
2003 Ma PC, Kijima T, Maulik G, Fox EA, Sattler M, Griffin JD, Johnson BE, Salgia R. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Research. 63: 6272-81. PMID 14559814  0.306
2003 Jafri NF, Ma PC, Maulik G, Salgia R. Mechanisms of metastasis as related to receptor tyrosine kinases in small-cell lung cancer. Journal of Environmental Pathology, Toxicology and Oncology : Official Organ of the International Society For Environmental Toxicology and Cancer. 22: 147-65. PMID 14529091 DOI: 10.1615/Jenvpathtoxoncol.V22.I3.10  0.498
2003 Kijima T, Maulik G, Ma PC, Madhiwala P, Schaefer E, Salgia R. Fibronectin enhances viability and alters cytoskeletal functions (with effects on the phosphatidylinositol 3-kinase pathway) in small cell lung cancer. Journal of Cellular and Molecular Medicine. 7: 157-64. PMID 12927054 DOI: 10.1111/J.1582-4934.2003.Tb00214.X  0.387
2003 Ma PC, Maulik G, Christensen J, Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Reviews. 22: 309-25. PMID 12884908 DOI: 10.1023/A:1023768811842  0.435
Show low-probability matches.